

Supporting Information

© Wiley-VCH 2013

69451 Weinheim, Germany

Desymmetrization of *meso*-2,5-Diallylpyrrolidiny Ureas through Asymmetric Palladium-Catalyzed Carboamination: Stereocontrolled Synthesis of Bicyclic Ureas**

*Nicholas R. Babij and John P. Wolfe**

ange_201302720_sm_miscellaneous_information.pdf

Supporting Information

Experimental procedures and characterization data for new compounds in Tables 1–2, Schemes 2–3, and Equation 1.


Table of Contents

General Considerations	S1
Preparation and Characterization of <i>meso</i> - <i>N</i> -Aryl-2,5-Diallylpyrrolidine-1-Carboxamide Substrates	S2
Preparation and Characterization of Bicyclic Urea Products	S7
Deprotection of Bicyclic Urea Product 8c	S22
Conversion of Bicyclic Urea Product 8c to Tricyclic Guanidine 12	S23
Conversion of Bicyclic Urea Product 8c to 9- <i>epi</i> -Batzelladine K 16	S25
Assignment of Stereochemistry	S28
References	S34
Copies of NMR Spectra and HPLC traces	S35

General: All reactions were carried out under a nitrogen atmosphere in flame-dried glassware unless otherwise noted. Tris(dibenzylidene)acetone dipalladium, tri(2-furyl)phosphine, and (*S*)-Siphos-PE were purchased from Strem Chemical Co. and used without purification. Tricyclohexylphosphonium tetrafluoroborate was purchased from Acros Chemical Co. and used without further purification. 2-Di-*tert*-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropyl-1,1'-biphenyl was purchased from Sigma-Aldrich and used without further purification. All other reagents were obtained from commercial sources and were used as obtained unless otherwise noted. NaO*t*Bu and CuCl were stored in the glove box and removed prior to use. BF₃OEt₂ and POCl₃ were purified by distillation under N₂ prior to use. (*Z*)-1-bromobutene^[1] was prepared according to a slight modification of a literature procedure; the preparation was conducted at rt instead of using microwave heating. (*Z*)-1-bromohexene^[2] and (*E*)-1-bromohexene^[2] were prepared according to published procedures. Toluene, THF, diethyl ether and dichloromethane


were purified using a GlassContour solvent purification system. Yields refer to isolated yields of compounds estimated to be $\geq 95\%$ pure as determined by ^1H NMR analysis unless otherwise noted. The yields reported in the supporting information describe the result of a single experiment, whereas yields reported in Tables 1–2, Scheme 2, and Equation 1 are average yields of two or more experiments. Thus, the yields reported in the supporting information may differ from those shown in Tables 1–2, Scheme 2, and Equation 1. Structural and stereochemical assignments were made on the basis of 2-D COSY, and NOESY experiments. Ratios of diastereomers were determined by ^1H NMR analysis. The reported optical rotation values refer to measurements taken of the isolated mixtures of diastereomers upon which chemical yields were based. Ratios of enantiomers were determined by HPLC analysis. Although diastereomers were not easily separable by chromatography, for most examples (with the exception of **8i** and **8j**) it was possible to separate small amounts of the pure ($>20:1$ dr) major diastereomer for chiral HPLC analysis.

Preparation and Characterization of *meso*-*N*-Aryl-2,5-Diallylpyrrolidine-1-Carboxamide Substrates



(±)-*tert*-Butyl octa-1,7-dien-4-ylcarbamate (S1). The title compound was prepared by modifying a procedure published by Veenstra.^[31] A flame-dried flask was cooled under a stream of N_2 , charged with dichloromethane (60 mL) and cooled to $0\text{ }^\circ\text{C}$. Pent-4-enal (2.96 mL, 30 mmol), allyltrimethylsilane (4.77 mL, 30 mmol) and *tert*-butyl carbamate (3.5 g, 30 mmol) were added to the flask and the resulting solution was stirred for 15 min at $0\text{ }^\circ\text{C}$. Distilled BF_3OEt_2 (2.3 mL, 18 mmol) was added and the reaction mixture was stirred for 30 min at $0\text{ }^\circ\text{C}$. The mixture was gradually warmed to rt and stirred for 30 min. The reaction was then quenched with saturated aqueous NaHCO_3 (20 mL) and stirred for 5 min at rt. The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was washed with saturated aqueous NaHCO_3 (20 mL) and then the combined aqueous layers were extracted with dichloromethane (15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 3.8 g (56%) of the title compound as a clear colorless oil. This compound was found to exist as a mixture of rotamers as judged by ^1H and ^{13}C NMR analysis; data are for the mixture. ^1H NMR (500 MHz, CDCl_3) δ 5.84–5.73 (m, 2 H), 5.10–4.95


(m, 4 H), 4.33 (d, br, $J = 7.5$ Hz, 1 H), 3.66 (d, br, $J = 4.5$ Hz, 1 H), 2.26–2.07 (m, 4 H), 1.60–1.55 (m, 1 H), 1.48–1.40 (m, 1 H), 1.43 (s, 9 H); ^{13}C NMR (175 MHz, CDCl_3) δ 155.5, 138.0, 134.4, 117.7, 114.9, 79.0, 49.6, 39.5, 33.9, 30.2, 28.4; IR (film) 3337, 1684 cm^{-1} . MS (ESI) 248.1621 (248.1621 calcd for $\text{C}_{13}\text{H}_{23}\text{NO}_2$, $\text{M} + \text{Na}^+$).




(±)-(E,2R*,5S*)-tert-Butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate (S2). A flame-dried Schlenk flask was cooled under a stream of N_2 and charged with $\text{Pd}_2(\text{dba})_3$ (81 mg, 0.089 mmol), tri(2-furyl)phosphine (82 mg, 0.36 mmol) and NaOtBu (853 mg, 8.9 mmol). The flask was purged with N_2 , then a solution of **S1** (1.0 g, 4.4 mmol) in freshly distilled xylenes (22.2 mL) was added via syringe and the resulting mixture was stirred at rt for 5 min. (E)-(2-bromovinyl)trimethylsilane (1.36 mL, 8.9 mmol) was added and the flask was heated to 137 °C and stirred overnight (ca. 14 h). The mixture was cooled to room temperature and saturated aqueous NH_4Cl (10 mL) and ethyl acetate (10 mL) were added. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (20 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 1.11 g (77%) of the title compound as a dark red-brown oil. This compound was found to exist as a mixture of rotamers as judged by ^1H and ^{13}C NMR analysis; data are for the mixture. ^1H NMR (500 MHz, CDCl_3) δ 5.98–5.92 (m, 1 H), 5.78–5.70 (m, 1 H), 5.68 (d, $J = 18.5$ Hz, 1 H), 5.06–5.01 (m, 2 H), 3.92–3.68 (m, 2 H), 2.64–2.41 (m, 2 H), 2.34 (dt, $J = 8.0, 13.0$ Hz, 1 H), 2.09 (dt, $J = 8.0, 13.0$ Hz, 1 H), 1.87–1.82 (m, 2 H), 1.68–1.64 (m, 2 H), 1.46 (s, 9 H), 0.03 (s, 9 H); ^{13}C NMR (125 MHz, CDCl_3) δ 154.7, 143.2, 135.4, 132.9, 116.8, 79.0, 58.0, 57.9, 42.1, 42.0, 40.0, 39.8, 28.5, –1.2; IR (film) 1692 cm^{-1} . MS (ESI) 346.2174 (346.2173 calcd for $\text{C}_{18}\text{H}_{33}\text{NO}_2\text{Si}$, $\text{M} + \text{Na}^+$).

General Procedure for Synthesis of meso-N-Aryl-2,5-Diallylpyrrolidine-1-Carboxamide Substrates 7. A round-bottom flask equipped with a stirbar was charged with **S2** (1.0 equiv) and dichloromethane (0.2 M). Trifluoroacetic acid (1.0 M) was added to the flask and the mixture was heated to reflux and stirred overnight. The solution was cooled to rt, diluted with water, basified with NH_4OH to pH > 12, and transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3 x 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude

product was dissolved in dichloromethane (0.2 M) and the appropriate isocyanate (1.1 equiv) was added. The reaction mixture was stirred at rt until starting material had been completely consumed as judged by TLC analysis (ca. 1 h). The crude reaction mixture was concentrated *in vacuo*, and purified by flash chromatography on silica gel.




(2S,5R)-2,5-Diallyl-N-(4-methoxyphenyl)pyrrolidine-1-carboxamide (7a). The title compound was prepared from **S2** (2.13 g, 6.6 mmol) and 4-methoxyphenyl isocyanate (940 μL , 7.3 mmol) in two steps via the general procedure described above. This procedure afforded 1.2 g (61%) of the title compound as a white solid: mp = 63–65 $^{\circ}\text{C}$. ^1H NMR (700 MHz, CDCl_3) δ 7.25 (d, J = 8.4 Hz, 2 H), 6.82 (d, J = 9.1 Hz, 2 H), 6.33 (s, 1H), 5.91–5.85 (m, 2 H), 5.20–5.15 (m, 4 H), 3.99–3.96 (m, 2 H), 3.77 (s, 3 H), 2.55 (dt, J = 14.0, 7.0 Hz, 2 H), 2.24 (dt, J = 7.0, 14.0 Hz, 2 H), 2.02–1.97 (m, 2 H), 1.78–1.74 (m, 2 H); ^{13}C NMR (175 MHz, CDCl_3) δ 155.5, 155.2, 135.2, 132.3, 121.4, 118.0, 114.1, 58.8, 55.5, 40.2, 29.5; IR (film) 3311, 1635 cm^{-1} . MS (ESI) 301.1917 (301.1911 calcd for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_2$, $\text{M} + \text{H}^+$).




(2S,5R)-2,5-Diallyl-N-(3,4-dimethoxyphenyl)pyrrolidine-1-carboxamide (7b). The title compound was prepared from **S2** (965 mg, 2.98 mmol) and 3,4-dimethoxyphenyl isocyanate (488 μL , 3.3 mmol) in two steps via the general procedure described above. This procedure afforded 542 mg (55%) of the title compound as a tan solid: mp = 112–114 $^{\circ}\text{C}$. ^1H NMR (500 MHz, CDCl_3) δ 7.27 (d, J = 2.1 Hz, 1 H), 6.77 (d, J = 8.4 Hz, 1 H), 6.62 (dd, J = 2.8, 8.4 Hz, 1 H), 6.36 (s, 1H), 5.91–5.86 (m, 2 H), 5.21–5.16 (m, 4 H), 4.01–3.97 (m, 2 H), 3.88 (s, 3 H), 3.84 (s, 3 H), 2.57 (dt, J = 6.3, 13.3 Hz, 2 H), 2.25 (dt, J = 7.7, 13.3 Hz, 2 H), 2.03–1.99 (m, 2 H),

1.79–1.75 (m, 2 H); ^{13}C NMR (175 MHz, CDCl_3) δ 155.1, 149.1, 144.8, 135.2, 133.0, 118.1, 111.4, 110.9, 104.7, 58.7, 56.2, 55.9, 40.2, 29.5; IR (film) 3327, 1635 cm^{-1} . MS (ESI) 331.2018 (331.2016 calcd for $\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_3$, $\text{M} + \text{H}^+$).




(2S,5R)-2,5-Diallyl-N-(4-chlorophenyl)pyrrolidine-1-carboxamide (7c). The title compound was prepared from **S2** (1.05 g, 3.2 mmol) and 4-chlorophenyl isocyanate (541 mg, 3.5 mmol) in two steps via the general procedure described above. This procedure afforded 574 mg (58%) of the title compound as a white solid: mp = 91–93 °C. ^1H NMR (500 MHz, CDCl_3) δ 7.30 (d, J = 9.0 Hz, 2 H), 7.21 (d, J = 9.0 Hz, 2 H), 6.51 (s, 1H), 5.91–5.85 (m, 2 H), 5.22–5.16 (m, 4 H), 4.00–3.95 (m, 2 H), 2.55 (dt, J = 14.0, 6.5 Hz, 2 H), 2.25 (dt, J = 14.0, 7.5 Hz, 2 H), 2.03–1.97 (m, 2 H), 1.79–1.74 (m, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 154.5, 137.9, 135.1, 128.7, 127.4, 120.3, 118.3, 58.9, 40.1, 29.6; IR (film) 3318, 1640 cm^{-1} . MS (ESI) 327.1242 (327.1235 calcd for $\text{C}_{17}\text{H}_{21}\text{ClN}_2\text{O}$, $\text{M} + \text{Na}^+$).




(2S,5R)-2,5-Diallyl-N-(4-bromophenyl)pyrrolidine-1-carboxamide (7d). The title compound was prepared from **S2** (1.2 g, 3.7 mmol) and 4-bromophenyl isocyanate (806 mg, 4.1 mmol) in two steps via the general procedure described above. This procedure afforded 827 mg (64%) of the title compound as a off-white solid: mp = 101–104 °C. ^1H NMR (700 MHz, CDCl_3) δ 7.37 (d, J = 7.7 Hz, 2 H), 7.25 (d, J = 7.7 Hz, 2 H), 6.49 (s, 1H), 5.91–5.85 (m, 2 H), 5.21–5.17 (m, 4 H), 3.99–3.97 (m, 2 H), 2.55 (dt, J = 6.3, 14.0 Hz, 2 H), 2.25 (dt, J = 7.0, 14.0 Hz, 2 H), 2.03–1.99 (m, 2 H), 1.80–1.77 (m, 2 H); ^{13}C NMR (175 MHz, CDCl_3) δ 154.5, 138.4, 135.1, 131.7, 120.7,

118.3, 115.0, 58.9, 40.1, 29.6; IR (film) 3316, 1635 cm^{-1} . MS (ESI) 349.0912 (349.0910 calcd for $\text{C}_{17}\text{H}_{21}\text{BrN}_2\text{O}$, $\text{M} + \text{H}^+$).



(2S,5R)-2,5-Diallyl-N-(4-cyanophenyl)pyrrolidine-1-carboxamide (7e). The title compound was prepared from **S2** (1.12 g, 3.46 mmol) and 4-cyanophenyl isocyanate (549 mg, 3.81 mmol) in two steps via the general procedure described above. This procedure afforded 613 mg (60%) of the title compound as a off-white solid: mp = 76–79 °C. ^1H NMR (700 MHz, CDCl_3) δ 7.36 (d, $J = 7.7$ Hz, 2 H), 7.25 (d, $J = 7.7$ Hz, 2 H), 6.49 (s, 1H), 5.92–5.86 (m, 2 H), 5.21–5.17 (m, 4 H), 4.02–3.96 (m, 2 H), 2.55 (dt, $J = 6.3, 14.0$ Hz, 2 H), 2.25 (dt, $J = 7.0, 14.0$ Hz, 2 H), 2.03–1.99 (m, 2 H), 1.80–1.77 (m, 2 H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.9, 143.5, 135.0, 133.1, 119.2, 118.6, 118.6, 105.1, 59.1, 39.9, 29.6; IR (film) 3365, 1652 cm^{-1} . MS (ESI) 296.1756 (296.1757 calcd for $\text{C}_{18}\text{H}_{21}\text{N}_3\text{O}$, $\text{M} + \text{H}^+$).



(2S,5R)-2,5-Diallyl-N-(4-nitrophenyl)pyrrolidine-1-carboxamide (7f). The title compound was prepared from **S2** (660 mg, 2.04 mmol) and 4-nitrophenyl isocyanate (368 mg, 2.24 mmol) in two steps via the general procedure described above. This procedure afforded 366 mg (57%) of the title compound as a pale-yellow solid: mp = 96–97 °C. ^1H NMR (700 MHz, CDCl_3) δ 8.15 (d, $J = 9.1$ Hz, 2 H), 7.50 (d, $J = 9.1$ Hz, 2 H), 6.93 (s, 1H), 5.94–5.88 (m, 2 H), 5.25–5.21 (m, 4 H), 4.04–4.01 (m, 2 H), 2.56 (dt, $J = 7.0, 13.3$ Hz, 2 H), 2.29 (dt, $J = 7.0, 14.0$ Hz, 2 H), 2.07–2.03 (m, 2 H), 1.83–1.79 (m, 2 H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.7, 145.5, 142.2, 135.0, 125.1,


118.8, 117.8, 59.2, 39.9, 29.7; IR (film) 3331, 1652 cm^{-1} . MS (ESI) 316.1656 (316.1656 calcd for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_3$, $\text{M} + \text{H}^+$).

Preparation and Characterization of Bicyclic Urea Products


General Procedure for Synthesis of Racemic Bicyclic Ureas (for HPLC assays). A flame-dried Schlenk tube was cooled under vacuum and charged with the appropriate *meso-N*-aryl-2,5-diallylpyrrolidine-1-carboxamide substrate (1.0 equiv), $\text{Pd}_2(\text{dba})_3$ (0.02 equiv), $\text{PCy}_3\text{:HBF}_4$ (0.08 equiv), and NaOtBu (1.5 equiv). The flask was evacuated and purged with N_2 . Toluene (0.2 M) was added via syringe and the resulting mixture was stirred at rt for 2 min. The appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was heated to 100 °C and stirred for 2 h. The mixture was cooled to room temperature and saturated aqueous NH_4Cl (5 mL/mmol substrate) and ethyl acetate (5 mL/mmol substrate) were added. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (5 mL/mmol substrate). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel.

General Procedure for Synthesis of Enantiomerically-Enriched Bicyclic Ureas

A flame-dried Schlenk tube was cooled under vacuum and charged with the appropriate *meso-N*-aryl-2,5-diallylpyrrolidine-1-carboxamide substrate (1.0 equiv), $\text{Pd}_2(\text{dba})_3$ (0.02 equiv), (S)-Siphos-PE (0.08 equiv), and NaOtBu or NaOMe (1.5 equiv). The flask was evacuated and purged with N_2 . Toluene (0.2 M) was added via syringe and the resulting mixture was stirred at rt for 2 min. The appropriate aryl or alkenyl bromide (1.5 equiv) was added and the tube was heated to 100 °C. The solution was stirred for 2 h or until the starting material was completely consumed as judged by TLC analysis. The mixture was cooled to room temperature and saturated aqueous NH_4Cl (5 mL/mmol substrate) and ethyl acetate (5 mL/mmol substrate) were added. 6 M HCl was used instead of NH_4Cl to remove aniline side products if column chromatography could not separate the desired product from aniline side products. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (5 mL/mmol substrate). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel.




(+)-(Z,3S,4aS,7R)-7-Allyl-2-(4-methoxyphenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8a). The general procedure was employed for the coupling of **7a** (60 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 μ L, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 48 mg (68%) of the title compound as a brown oil and as a 7:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ +9.5 (c 4.3, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.14 (d, *J* = 8.4 Hz, 2 H), 6.88 (d, *J* = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.43 (dt, *J* = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.03 (d, *J* = 17.5 Hz, 1 H), 5.00 (d, *J* = 9.8 Hz, 1 H), 3.99 (dt, *J* = 2.1, 9.1 Hz, 1 H), 3.82–3.78 (m, 1 H), 3.79 (s, 3 H), 3.65 (ddt, *J* = 2.1, 4.9, 11.2 Hz, 1 H), 2.80 (dd, *J* = 5.6, 13.3 Hz, 1 H), 2.29–2.27 (m, 1 H), 2.18–2.15 (m, 2 H), 2.08 (dt, *J* = 8.4, 13.3 Hz, 1 H) 1.99–1.88 (m, 4 H), 1.83 (dd, *J* = 6.3, 12.6 Hz, 1 H) 1.68–1.60 (m, 2 H), 0.89 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 157.6, 154.2, 135.8, 135.1, 134.6, 129.3, 124.2, 116.8, 114.1, 58.3, 57.3, 55.4, 52.7, 37.8, 31.3, 31.0, 30.9, 27.8, 20.7, 14.0; IR (film) 1642 cm⁻¹. MS (ESI) 355.2382 (355.2380 calcd for C₂₂H₃₀N₂O₂, M + H⁺). The enantiopurity was determined to be 86:14 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 2.5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 44.2 and 49.1 min).




(+)-(Z,3S,4aS,7R)-7-Allyl-2-(3,4-dimethoxyphenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8b). The general procedure was employed for the coupling of **7b** (66 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 μ L, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 30 mg (39%) of the title compound as a brown oil and as a 7:1 mixture

of diastereomers as determined by ^1H NMR analysis: $[\alpha]_D^{23} +7.0$ (c 2.9, CH_2Cl_2). Data are for the major isomer. ^1H NMR (700 MHz, CDCl_3) δ 6.83 (d, $J = 8.4$ Hz, 1 H), 6.78–6.77 (m, 2 H), 5.77–5.71 (m, 1 H), 5.44 (dt, $J = 7.0, 10.5$ Hz, 1 H) 5.13–5.09 (m, 1 H), 5.03 (d, $J = 16.8$ Hz, 1 H), 5.00 (d, $J = 10.5$ Hz, 1 H), 4.01 (dt, $J = 2.8, 9.1$ Hz, 1 H), 3.86 (s, 6 H), 3.85–3.81 (m, 1 H), 3.66 (ddt, $J = 2.1, 5.6, 11.2$ Hz, 1 H), 2.80 (dd, $J = 5.6, 12.6$ Hz, 1 H), 2.30–2.28 (m, 1 H), 2.18–2.15 (m, 2 H), 2.07 (dt, $J = 8.4, 13.3$ Hz, 1 H) 2.00–1.96 (m, 1 H), 1.93–1.87 (m, 3 H), 1.83 (dd, $J = 7.0, 12.6$ Hz, 1 H) 1.69–1.63 (m, 2 H), 0.89 (t, $J = 7.7$ Hz, 3 H); ^{13}C NMR (175 MHz, CDCl_3) δ 154.1, 148.9, 147.2, 135.8, 135.4, 134.7, 124.2, 120.1, 116.8, 112.3, 111.1, 58.5, 57.3, 56.0, 55.9, 52.7, 37.8, 31.3, 31.1, 30.9, 27.7, 20.7, 14.1; IR (film) 1641 cm^{-1} . MS (ESI) 385.2486 (385.2486 calcd for $\text{C}_{23}\text{H}_{32}\text{N}_2\text{O}_3$, $\text{M} + \text{H}^+$). The enantiopurity was determined to be 82:18 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 20.4 and 23.5 min).




(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8c). The general procedure was employed for the coupling of **7c** (305 mg, 1.0 mmol) and (Z)-1-bromobut-1-ene (750 μL , 1.5 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd_2dba_3 (18.3 mg, 0.02 mmol), and (S)-Siphos-PE (40.4 mg, 0.08 mmol). This procedure afforded 288 mg (80%) of the title compound as a yellow oil: $[\alpha]_D^{23} -14.3$ (c 5.3, CH_2Cl_2). ^1H NMR (700 MHz, CDCl_3) δ 7.31 (d, $J = 8.4$ Hz, 2 H), 7.19 (d, $J = 8.4$ Hz, 2 H), 5.77–5.71 (m, 1 H), 5.45 (dt, $J = 7.0, 10.5$ Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, $J = 16.8$ Hz, 1 H), 5.01 (d, $J = 10.5$ Hz, 1 H), 4.01 (dt, $J = 2.8, 9.1$ Hz, 1 H), 3.90 (dt, $J = 4.2, 10.5$ Hz, 1 H), 3.66 (ddt, $J = 2.1, 4.9, 11.2$ Hz, 1 H), 2.78 (dd, $J = 5.6, 12.6$ Hz, 1 H), 2.23–2.15 (m, 3 H), 2.07 (dt, $J = 9.1, 13.3$ Hz, 1 H) 1.99 (dt, $J = 6.3, 11.2$ Hz, 1 H), 1.93–1.88 (m, 3 H), 1.84 (dd, $J = 6.3, 12.6$ Hz, 1 H) 1.69–1.64 (m, 2 H), 0.90 (t, $J = 7.7$ Hz, 3 H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.7, 140.8, 135.6, 134.9, 131.2, 129.3, 128.9, 123.8, 117.0, 58.0, 57.4, 52.8, 37.7, 31.3, 31.0, 30.9, 27.8, 20.7, 14.0; IR (film) 1643 cm^{-1} . MS (ESI) 359.1887 (359.1885 calcd for $\text{C}_{21}\text{H}_{27}\text{ClN}_2\text{O}$, $\text{M} +$


H⁺). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 190 nm, RT= 13.4 and 18.1 min).



(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-bromophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8d). The general procedure was employed for the coupling of **7d** (70 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 μ L, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 15 mg (18%) of the title compound as a brown oil and as a 18:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ -21.1 (c 0.5, CH₂Cl₂). This material also contained ca. 20% of an unidentified side product. Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.46 (d, *J* = 8.4 Hz, 2 H), 7.14 (d, *J* = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.45 (dt, *J* = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, *J* = 17.5 Hz, 1 H), 5.01 (d, *J* = 10.5 Hz, 1 H), 4.01 (dt, *J* = 2.8, 8.4 Hz, 1 H), 3.90 (dt, *J* = 4.9, 10.5 Hz, 1 H), 3.66 (ddt, *J* = 2.8, 5.6, 11.2 Hz, 1 H), 2.78 (dd, *J* = 5.6, 12.6 Hz, 1 H), 2.23–2.15 (m, 3 H), 2.07 (dt, *J* = 8.4, 13.3 Hz, 1 H), 1.99 (dt, *J* = 5.6, 11.9 Hz, 1 H), 1.95–1.88 (m, 3 H), 1.84 (dd, *J* = 6.3, 12.6 Hz, 1 H), 1.69–1.63 (m, 2 H), 0.90 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.6, 141.4, 135.6, 134.9, 131.9, 129.7, 123.8, 119.2, 117.0, 57.9, 57.4, 52.7, 37.7, 31.3, 31.0, 30.8, 27.7, 20.7, 14.0; IR (film) 1645 cm⁻¹. MS (ESI) 403.1379 (403.1380 calcd for C₂₁H₂₇BrN₂O, M + H⁺). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 14.5 and 20.0 min).




(-)-4-[(Z,3S,4aS,7R)-7-Allyl-1-oxo-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-2(1H)-yl]benzonitrile (8e). The general procedure was employed for the coupling of **7e** (59 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 μ L, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 29 mg (41%) of the title compound as a brown oil and as a 17:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ -71.0 (c 2.9, CH₂Cl₂). This material also contained ca. 5% of 4-aminobenzonitrile. Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.62 (d, *J* = 9.1 Hz, 2 H), 7.39 (d, *J* = 9.1 Hz, 2 H), 5.76–5.71 (m, 1 H), 5.45 (dt, *J* = 7.0, 11.2 Hz, 1 H), 5.12–5.08 (m, 1 H), 5.04 (d, *J* = 16.1 Hz, 1 H), 5.02 (d, *J* = 9.1 Hz, 1 H), 4.07 (dt, *J* = 4.9, 10.5 Hz, 1 H), 4.02 (dt, *J* = 2.1, 8.4, Hz 1 H), 3.68 (ddt, *J* = 2.1, 5.6, 11.2 Hz, 1 H), 2.76 (dd, *J* = 6.3, 12.6 Hz, 1 H), 2.23 (d, *J* = 12.6 Hz, 1 H), 2.20–2.14 (m, 2 H), 2.06 (dt, *J* = 8.4, 13.3 Hz, 1 H), 2.03–2.00 (m, 1 H), 1.97–1.85 (m, 4 H), 1.71–1.63 (m, 2 H), 0.89 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.1, 146.6, 135.3, 135.2, 132.6, 127.8, 123.4, 118.9, 117.2, 108.5, 57.7, 57.4, 52.7, 37.4, 31.4, 31.0, 30.8, 27.7, 20.7, 14.0; IR (film) 1648 cm⁻¹. MS (ESI) 350.2227 (350.2227 calcd for C₂₂H₂₇N₃O, M + H⁺). The enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 33.2 and 42.9 min).




(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-nitrophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8f). A modification of the general procedure was employed for the coupling of **7f** (63 mg, 0.2 mmol) and (Z)-1-bromobut-1-ene (150 μ L, 0.3 mmol, 2.0 M solution in toluene), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8

mg, 0.016 mmol). In contrast to the general procedure, this reaction was run overnight (16 h) at 120 °C. This procedure afforded 18 mg (24%) of the title compound as a yellow oil and as a 20:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ –281.3 (c 1.1, CH₂Cl₂). This material also contained ca. 8% of unreacted starting material and ca. 3% of a bicyclic urea side product lacking the butenyl group (tentatively assigned as 7-allyl-3-methyl-2-(4-nitrophenyl)-4a,5,6,7-tetrahydropyrrolo[1,2-c]pyrimidin-1(2*H*)-one). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 8.21 (d, *J* = 9.1 Hz, 2 H), 7.46 (d, *J* = 9.1 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.46 (dt, *J* = 7.0, 11.2 Hz, 1 H), 5.12 (ddt, *J* = 2.1, 8.4, 17.5 Hz, 1 H), 5.07–5.03 (m, 2 H), 4.15 (dt, *J* = 4.,9 9.8 Hz, 1 H), 4.05 (dt, *J* = 2.8, 9.1 Hz, 1 H), 3.70 (ddt, *J* = 2.8, 5.6, 11.2 Hz, 1 H), 2.78 (dd, *J* = 5.6, 13.3 Hz, 1 H), 2.25 (d, *J* = 13.3 Hz, 1 H), 2.23–2.16 (m, 2 H), 2.10–2.02 (m, 2 H) 1.97–1.87 (m, 4 H), 1.73–1.66 (m, 2 H), 0.90 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.0, 148.5, 144.4, 135.3, 135.3, 127.2, 124.1, 123.3, 117.3, 57.8, 57.4, 52.7, 37.3, 31.5, 31.0, 30.8, 27.7, 20.8, 14.0; IR (film) 1649 cm⁻¹. MS (ESI) 370.2126 (370.2125 calcd for C₂₁H₂₇N₃O₃, M + H⁺). The enantiopurity was determined to be 96:4 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 1.5 mL/min, λ 310 nm, RT= 19.1 and 26.2 min).




(–)-(E,3*S*,4*aS*,7*R*)-7-Allyl-2-(4-chlorophenyl)-3-(hept-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2*H*)-one (8g). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and (*E*)-1-bromohex-1-ene (49 mg, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). 6 M HCl was used in the workup to remove 4-chloroaniline side product. This procedure afforded 44 mg (57%) of the title compound as a yellow oil: [α]_D²³ –30.3 (c 1.9, CH₂Cl₂). This material also contained ca. 15% of a regioisomeric bicyclic urea product generated from the coupling of **7c** and 2-bromohex-1-ene (tentatively assigned as (3*S*,4*aS*,7*R*)-7-allyl-2-(4-chlorophenyl)-3-(2-methylenehexyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2*H*)-one). Data are for the major isomer. ¹H NMR (500 MHz, CDCl₃) δ 7.31 (d, *J* = 9.0 Hz, 2 H), 7.17 (d, *J* = 9.0 Hz, 2 H), 5.78–5.70 (m, 1 H), 5.41–5.36 (m, 1 H), 5.17–5.10 (m, 1 H), 5.05–5.00 (m, 2 H), 4.00 (dt, *J* = 2.5, 8.5 Hz, 1 H),


3.92–3.87 (m, 1 H), 3.65 (ddt, $J = 2.5, 5.5, 11.0$ Hz, 1 H), 2.79 (dd, $J = 6.0, 13.5$ Hz, 1 H), 2.28–2.23 (m, 2 H), 2.10–1.98 (m, 3 H), 1.95–1.87 (m, 3 H), 1.84 (dd, $J = 6.5, 12.5$ Hz, 1 H) 1.69–1.62 (m, 2 H), 1.29–1.26 (m, 4 H), 0.87 (t, $J = 7.0$ Hz, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.7, 140.9, 135.6, 134.6, 131.2, 129.4, 128.8, 125.1, 116.9, 57.9, 57.4, 52.6, 37.7, 36.9, 32.2, 31.4, 30.8, 27.8, 22.1, 13.9 (one carbon signal is absent due to incidental equivalence); IR (film) 1643 cm^{-1} . MS (ESI) 387.2207 (387.2198 calcd for $\text{C}_{23}\text{H}_{31}\text{ClN}_2\text{O}$, $\text{M} + \text{H}^+$). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 1.5% IPA/Hexanes, 1.5 mL/min, λ 205 nm, RT= 20.0 and 37.5 min).



(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(hept-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8h). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and (*Z*)-1-bromohex-1-ene (49 mg, 0.3 mmol), using a catalyst composed of Pd_2dba_3 (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). 6 M HCl was used in the workup to remove 4-chloroaniline side product. This procedure afforded 47 mg (61%) of the title compound as a yellow brown oil: $[\alpha]_{\text{D}}^{23} -14.8$ (c 3.5, CH_2Cl_2). Data are for the major isomer. ^1H NMR (700 MHz, CDCl_3) δ 7.31 (d, $J = 9.1$ Hz, 2 H), 7.19 (d, $J = 8.4$ Hz, 2 H), 5.77–5.71 (m, 1 H), 5.45 (dt, $J = 7.0, 11.2$ Hz, 1 H), 5.15–5.11 (m, 1 H), 5.05–5.00 (m, 2 H), 4.01 (dt, $J = 2.8, 8.4$ Hz, 1 H), 3.91–3.88 (m, 1 H), 3.66 (ddt, $J = 2.1, 4.9, 11.2$ Hz, 1 H), 2.78 (dd, $J = 8.4, 13.3$ Hz, 1 H), 2.24–2.14 (m, 3 H), 2.07 (dt, $J = 8.4, 14.0$ Hz, 1 H), 2.00–1.97 (m, 1 H) 1.95–1.83 (m, 4 H), 1.70–1.62 (m, 2 H), 1.25–1.24 (m, 4 H), 0.86 (t, $J = 7.0$ Hz, 3 H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.7, 140.8, 135.6, 133.4, 131.3, 129.4, 128.9, 124.4, 117.0, 58.1, 57.4, 52.8, 37.7, 31.6, 31.3, 31.0, 30.8, 27.8, 27.2, 22.3, 13.9; IR (film) 1642 cm^{-1} . MS (ESI) 387.2203 (387.2198 calcd for $\text{C}_{23}\text{H}_{31}\text{ClN}_2\text{O}$, $\text{M} + \text{H}^+$). The enantiopurity was determined to be 95:5 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 1.5% IPA/Hexanes, 1.5 mL/min, λ 254 nm, RT= 20.9 and 36.2 min).




(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(3-methylbut-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8i). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 1-bromo-2-methyl-1-propene (31 μ L, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 37 mg (52%) of the title compound as a yellow oil and as a 10:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ -37.9 (c 2.2, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.30 (d, *J* = 7.7 Hz, 2 H), 7.18 (d, *J* = 9.1 Hz, 2 H), 5.74 (dddd, *J* = 6.3, 7.7, 10.5, 16.8 Hz, 1 H), 5.04 (dd, *J* = 2.1, 16.8 Hz, 1 H), 5.01 (d, *J* = 10.5 Hz, 1 H), 4.89 (dt, *J* = 1.4, 7.0 Hz, 1 H), 4.00 (dt, *J* = 2.8, 9.1 Hz, 1 H), 3.88–3.85 (m, 1 H), 3.66 (ddt, *J* = 2.8, 5.6, 11.2 Hz, 1 H), 2.79 (dd, *J* = 6.3, 12.6 Hz, 1 H), 2.21–2.16 (m, 2 H), 2.09–2.04 (m, 2 H), 2.02–1.99 (m, 1 H), 1.95–1.89 (m, 1 H), 1.84 (dd, *J* = 7.0, 12.6 Hz, 1 H) 1.68–1.62 (m, 2 H), 1.64 (s, 3 H), 1.47 (s, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.7, 140.9, 135.6, 134.9, 131.1, 129.3, 128.8, 119.6, 117.0, 58.3, 57.4, 52.8, 37.7, 32.2, 31.1, 30.9, 27.7, 25.7, 17.9; IR (film) 1643 cm⁻¹. MS (ESI) 359.1895 (359.1885 calcd for C₂₁H₂₇ClN₂O, M + H⁺). The enantiopurity was determined to be 94:6 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 13.8 and 24.0 min).




(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(2-methylallyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8j). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 2-bromopropene (89 μ L, 1.0 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 39 mg

(56%) of the title compound as a yellow oil and as a 20:1 mixture of diastereomers as determined by ^1H NMR analysis: $[\alpha]_D^{23} -33.5$ (c 2.9, CH_2Cl_2). Data are for the major isomer. ^1H NMR (700 MHz, CDCl_3) δ 7.31 (d, $J = 8.4$ Hz, 2 H), 7.19 (d, $J = 9.1$ Hz, 2 H), 5.77–5.71 (m, 1 H), 5.06–5.01 (m, 2 H), 4.79 (s, 1 H), 4.66 (s, 1 H), 4.09–4.06 (m, 1 H), 4.00 (dt, $J = 2.8, 8.4$ Hz, 1 H), 3.66 (ddt, $J = 2.8, 4.9, 11.2$ Hz, 1 H), 2.79 (dd, $J = 6.3, 12.6$ Hz, 1 H), 2.27–2.23 (m, 2 H), 2.12 (dd, $J = 11.2, 14.0$ Hz, 1 H) 2.07 (dt, $J = 8.4, 13.3$ Hz, 1 H), 2.03–1.99 (m, 1 H), 1.95–1.89 (m, 1 H), 1.85 (dd, $J = 7.0, 12.6$ Hz, 1 H) 1.68–1.64 (m, 2 H), 1.55 (s, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 153.7, 141.5, 140.7, 135.6, 131.2, 129.3, 128.9, 117.0, 113.9, 57.5, 55.8, 52.6, 41.8, 37.7, 30.8, 30.5, 27.8, 22.0; IR (film) 1641 cm^{-1} . MS (ESI) 345.1735 (345.1728 calcd for $\text{C}_{20}\text{H}_{25}\text{ClN}_2\text{O}$, $\text{M} + \text{H}^+$). The enantiopurity was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 3% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 22.8 and 28.4 min).




(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(4-methylbenzyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8k). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 4-bromotoluene (37 μL , 0.3 mmol), using a catalyst composed of Pd_2dba_3 (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 66 mg (83%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as determined by ^1H NMR analysis: $[\alpha]_D^{23} -125.6$ (c 3.1, CH_2Cl_2). Data are for the major isomer. ^1H NMR (700 MHz, CDCl_3) δ 7.36 (d, $J = 8.4$ Hz, 2 H), 7.26 (d, $J = 8.4$ Hz, 2 H), 7.06 (d, $J = 8.4$ Hz, 2 H), 6.86 (d, $J = 7.7$ Hz, 2 H), 5.77–5.71 (m, 1 H), 5.04 (d, $J = 16.8$ Hz, 1 H), 5.01 (d, $J = 10.5$ Hz, 1 H), 4.10 (dt, $J = 4.9, 11.2$ Hz, 1 H), 4.03 (dt, $J = 2.8, 8.4$ Hz, 1 H), 3.76 (ddt, $J = 2.8, 5.6, 11.2$ Hz, 1 H), 2.90 (dd, $J = 2.8, 13.3$ Hz, 1 H), 2.81–2.78 (m, 1 H), 2.53 (dd, $J = 11.2, 14.0$ Hz, 1 H), 2.30 (s, 3 H), 2.09–2.04 (m, 2 H), 2.00 (dt, $J = 5.6, 11.9$ Hz, 1 H), 1.96–1.91 (m, 1 H), 1.85 (dd, $J = 5.6, 12.6$ Hz, 1 H) 1.64–1.59 (m, 1 H), 1.56 (dt, $J = 6.3, 12.6$ Hz, 1 H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.6, 140.8, 136.2, 135.6, 134.5, 131.3, 129.3, 129.3, 129.0, 128.9, 117.0, 59.8, 57.5, 52.6, 39.2, 37.6, 30.8, 30.1, 27.8, 21.0; IR (film) 1642 cm^{-1} . MS (ESI) 395.1887 (395.1885 calcd for $\text{C}_{24}\text{H}_{27}\text{ClN}_2\text{O}$, $\text{M} + \text{H}^+$). The enantiopurity was determined to be 92:8 er by

chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 254 nm, RT= 17.3 and 19.4 min).




(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(4-methoxybenzyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8I). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 4-bromoanisole (38 μ L, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 58 mg (70%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as determined by ¹H NMR analysis: $[\alpha]_D^{23}$ -169.4 (c 2.2, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.35 (d, *J* = 8.4 Hz, 2 H), 7.25 (d, *J* = 8.4 Hz, 2 H), 6.89 (d, *J* = 9.1 Hz, 2 H), 6.79 (d, *J* = 8.4 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.04 (d, *J* = 17.5 Hz, 1 H), 5.01 (d, *J* = 10.5 Hz, 1 H), 4.08 (dt, *J* = 4.2, 11.2 Hz, 1 H), 4.03 (dt, *J* = 2.1, 8.4 Hz, 1 H), 3.77 (s, 3 H), 3.77–3.72 (m, 1 H), 2.87 (dd, *J* = 3.5, 14.0 Hz, 1 H), 2.80 (dd, *J* = 6.3, 14.0 Hz, 1 H), 2.51 (dd, *J* = 11.2, 13.3 Hz, 1 H), 2.09–2.04 (m, 2 H), 2.00 (dt, *J* = 5.6, 11.9 Hz, 1 H), 1.96–1.91 (m, 1 H), 1.85 (dd, *J* = 7.0, 12.6 Hz, 1 H) 1.65–1.54 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 158.3, 153.6, 140.8, 135.6, 131.3, 130.0, 129.6, 129.3, 129.0, 117.0, 114.0, 59.9, 57.5, 55.2, 52.6, 38.7, 37.6, 30.8, 30.1, 27.8; IR (film) 1642 cm⁻¹. MS (ESI) 411.1834 (411.1834 calcd for C₂₄H₂₇ClN₂O₂, M + H⁺). The enantiopurity was determined to be 92:8 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 3% IPA/Hexanes, 0.75 mL/min, λ 204 nm, RT= 49.3 and 55.7 min).




(-)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8m). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol)

and bromobenzene (32 μ L, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 63 mg (83%) of the title compound as a pale brown foam oil and as a 7:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ -61.2 (c 5.6, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.36 (d, *J* = 9.1 Hz, 2 H), 7.27–7.25 (m, 4 H), 7.21–7.20 (m, 1 H), 6.98 (d, *J* = 7.0 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.00 (m, 2 H), 4.14 (dt, *J* = 4.9, 11.2 Hz, 1 H), 4.03 (dt, *J* = 2.1, 8.4 Hz, 1 H), 3.77 (ddt, *J* = 2.1, 4.9, 11.2 Hz, 1 H), 2.94 (dd, *J* = 3.5, 14.0 Hz, 1 H), 2.80 (dd, *J* = 6.3, 13.3 Hz, 1 H), 2.57 (dd, *J* = 11.2, 14.0 Hz, 1 H), 2.10–2.04 (m, 2 H), 2.03–2.00 (m, 1 H), 1.97–1.91 (m, 1 H), 1.86 (dd, *J* = 6.3, 12.6 Hz, 1 H) 1.66–1.54 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.6, 140.8, 137.6, 135.6, 131.4, 129.3, 129.1, 129.0, 128.6, 126.6, 117.0, 59.7, 57.5, 52.7, 39.6, 37.6, 30.8, 30.2, 27.8; IR (film) 1642 cm⁻¹. MS (ESI) 381.1736 (381.1728 calcd for C₂₃H₂₅ClN₂O, M + H⁺). The enantiopurity was determined to be 90:10 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 21.1 and 24.2 min).




(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-[4-(trifluoromethyl)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8n). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 4-bromobenzotrifluoride (42 μ L, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 66 mg (74%) of the title compound as a pale yellow oil and as a 5:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ -46.1 (c 6.0, CH₂Cl₂). Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.51 (d, *J* = 7.7 Hz, 2 H), 7.36 (d, *J* = 9.1 Hz, 2 H), 7.24 (d, *J* = 9.1 Hz, 2 H), 7.09 (d, *J* = 7.7 Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.01 (m, 2 H), 4.16 (dt, *J* = 4.2, 11.2 Hz, 1 H), 4.03 (dt, *J* = 2.1, 9.1 Hz, 1 H), 3.76 (ddt, *J* = 2.1, 5.6, 11.9 Hz, 1 H), 3.00 (dd, *J* = 3.5, 14.0 Hz, 1 H), 2.79 (dd, *J* = 5.6, 13.3 Hz, 1 H), 2.66 (dd, *J* = 11.2, 13.3 Hz, 1 H), 2.09–2.00 (m, 3 H), 1.98–1.93 (m, 1 H), 1.87 (dd, *J* = 6.3, 11.9 Hz, 1 H) 1.66–1.56 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 153.5, 141.7, 140.6, 135.5, 131.6, 129.4, 129.3, 129.2 (q, *J* = 37 Hz), 129.1, 125.6 (q, 3.3 Hz), 124.0 (q, *J* = 270 Hz), 117.1,

59.5, 57.6, 52.6, 39.6, 37.6, 30.8, 30.3, 27.8; IR (film) 1642 cm^{-1} . MS (ESI) 449.1600 (449.1602 calcd for $\text{C}_{24}\text{H}_{24}\text{ClF}_3\text{N}_2\text{O}$, $\text{M} + \text{H}^+$). The enantiopurity was determined to be 85:15 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 19.9 and 27.5 min).




(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-[4-(trifluoromethyl)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8n). A modified general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 4-bromobenzotrifluoride (42 μL , 0.3 mmol) using NaOMe (16.2 mg, 0.3 mmol) as base and a catalyst composed of Pd_2dba_3 (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 54 mg (60%) of the title compound as a pale yellow oil and as a 10:1 mixture of diastereomers as determined by ^1H NMR analysis: $[\alpha]_D^{23} -51.1$ (c 2.3, CH_2Cl_2). The enantiopurity was determined to be 90:10 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 205 nm, RT= 19.4 and 26.7 min). Spectroscopic data were identical to those provided above.




(-)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)-3-[4-(trifluoromethoxy)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8o). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 1-bromo-4-(trifluoromethoxy)benzene (45 μL , 0.3 mmol), using a catalyst composed of Pd_2dba_3 (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 63 mg (68%) of the title compound as a pale yellow oil and as a 8:1 mixture of diastereomers as determined by


^1H NMR analysis: $[\alpha]_{\text{D}}^{23} -48.7$ (c 5.7, CH_2Cl_2). Data are for the major isomer. ^1H NMR (700 MHz, CDCl_3) δ 7.35 (d, $J = 9.1$ Hz, 2 H), 7.24 (d, $J = 9.1$ Hz, 2 H), 7.10 (d, $J = 7.7$ Hz, 2 H), 6.99 (d, $J = 8.4$ Hz, 2 H), 5.77–5.71 (m, 1 H), 5.05–5.01 (m, 2 H), 4.13 (dt, $J = 4.2, 11.2$ Hz, 1 H), 4.03 (dt, $J = 2.8, 8.4$ Hz, 1 H), 3.75 (ddt, $J = 2.8, 4.9, 11.2$ Hz, 1 H), 2.93 (dd, $J = 4.2, 14.0$ Hz, 1 H), 2.79 (dd, $J = 6.3, 13.3$ Hz, 1 H), 2.60 (dd, $J = 10.5, 14.0$ Hz, 1 H), 2.10–2.00 (m, 3 H), 1.98–1.92 (m, 1 H), 1.86 (dd, $J = 6.3, 12.6$ Hz, 1 H) 1.67–1.57 (m, 2 H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.5, 147.9, 140.7, 136.7, 135.5, 131.5, 130.3, 129.3, 129.1, 121.2, 117.0, 59.6, 57.5, 52.6, 39.1, 37.6, 30.8, 30.3, 27.8 (the CF_3 carbon signal could not be determined due to the appearance of carbon signals from the minor diastereomer in the CF_3 region of the spectrum); IR (film) 1642 cm^{-1} . MS (ESI) 465.1557 (465.1551 calcd for $\text{C}_{24}\text{H}_{24}\text{ClF}_3\text{N}_2\text{O}_2$, $\text{M} + \text{H}^+$). The enantiopurity was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 17.1 and 19.8 min).



(-)-(3S,4aS,7R)-7-Allyl-3-benzyl-2-(4-chlorophenyl)-3-[4-(trifluoromethoxy)benzyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8o). A modified general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 1-bromo-4-(trifluoromethoxy)benzene (45 μL , 0.3 mmol) using NaOMe (16.2 mg, 0.3 mmol) as base and a catalyst composed of Pd_2dba_3 (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 48 mg (52%) of the title compound as a pale yellow oil and as an 17:1 mixture of diastereomers as determined by ^1H NMR analysis: $[\alpha]_{\text{D}}^{23} -55.6$ (c 1.5, CH_2Cl_2). The enantiopurity was determined to be 93:7 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 245 nm, RT= 16.8 and 19.8 min). Spectroscopic data were identical to those provided above.




(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(3-methoxybenzyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8p). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 3-bromoanisole (38 μ L, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 61 mg (74%) of the title compound as a yellow brown solid and as a 5:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ -65.1 (c 2.8, CH₂Cl₂). Mp = 132–137 °C. Data are for the major isomer. ¹H NMR (700 MHz, CDCl₃) δ 7.36 (d, *J* = 8.4 Hz, 2 H), 7.25 (d, *J* = 9.1 Hz, 2 H), 7.18 (t, *J* = 8.4 Hz, 1 H), 6.74 (dd, *J* = 2.1, 8.4 Hz, 1 H), 6.57 (d, *J* = 7.0 Hz, 1 H), 6.50 (s, 1 H), 5.77–5.71 (m, 1 H), 5.04 (dd, *J* = 1.4, 16.8 Hz, 1 H), 5.01 (dd, *J* = 1.4, 9.8 Hz, 1 H), 4.14 (dt, *J* = 4.2, 11.2 Hz, 1 H), 4.03 (dt, *J* = 2.1, 8.4 Hz, 1 H), 3.77 (s, 3 H), 3.78–3.73 (m, 1 H), 2.91 (dd, *J* = 3.5, 13.3 Hz, 1 H), 2.80 (dd, *J* = 5.6, 13.3 Hz, 1 H), 2.54 (dd, *J* = 11.2, 14.0 Hz, 1 H), 2.10–2.04 (m, 2 H), 2.03–1.99 (m, 1 H), 1.96–1.91 (m, 1 H), 1.85 (dd, *J* = 6.3, 12.6 Hz, 1 H), 1.65–1.56 (m, 2 H); ¹³C NMR (175 MHz, CDCl₃) δ 159.7, 153.6, 140.7, 139.2, 135.6, 131.4, 129.6, 129.3, 129.0, 121.4, 117.0, 115.3, 111.3, 59.6, 57.5, 55.2, 52.7, 39.7, 37.6, 30.8, 30.3, 27.8; IR (film) 1642 cm⁻¹. MS (ESI) 411.1841 (411.1834 calcd for C₂₄H₂₇ClN₂O₂, M + H⁺). The enantiopurity was determined to be 87:13 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 248 nm, RT= 27.2 and 30.6 min).



(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(naphthalen-2-ylmethyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8q). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 2-bromonaphthalene (62 mg, 0.3 mmol), using a catalyst composed of Pd₂dba₃ (3.7 mg, 0.004 mmol), and (S)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded


66 mg (77%) of the title compound as a white solid and as a 7:1 mixture of diastereomers as determined by ^1H NMR analysis: $[\alpha]_D^{23} -77.9$ (c 4.6, CH_2Cl_2). Data are for the major isomer. Mp = 63–65 °C. ^1H NMR (700 MHz, CDCl_3) δ 7.80 (d, $J = 7.7$ Hz, 1 H), 7.75 (t, $J = 7.7$ Hz, 2 H), 7.47–7.44 (m, 3 H), 7.38 (d, $J = 9.1$ Hz, 2 H), 7.31 (d, $J = 8.4$ Hz, 2 H), 7.07 (dd, $J = 0.7, 8.4$ Hz, 1 H), 5.78–5.72 (m, 1 H), 5.04 (d, $J = 16.8$ Hz, 1 H), 5.02 (d, $J = 9.8$ Hz, 1 H), 4.25 (dt, $J = 4.2, 11.2$ Hz, 1 H), 4.06 (dt, $J = 2.1, 9.8$ Hz, 1 H), 3.84 (ddt, $J = 2.1, 4.9, 11.2$ Hz, 1 H), 3.11 (dd, $J = 3.5, 14.0$ Hz, 1 H), 2.81 (dd, $J = 5.6, 13.3$ Hz, 1 H), 2.74 (dd, $J = 11.9, 14.0$ Hz, 1 H), 2.11–2.05 (m, 2 H), 2.04–1.94 (m, 2 H), 1.86 (dd, $J = 7.0, 12.6$ Hz, 1 H), 1.65–1.56 (m, 2 H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.6, 140.8, 135.6, 135.1, 133.4, 132.2, 131.4, 130.4, 129.4, 129.1, 128.4, 127.7, 127.3, 127.1, 126.3, 125.7, 117.0, 59.6, 57.5, 52.7, 37.6, 30.8, 31.0, 30.2, 27.8; IR (film) 1646 cm^{-1} . MS (ESI) 431.1886 (431.1885 calcd for $\text{C}_{27}\text{H}_{27}\text{ClN}_2\text{O}$, $\text{M} + \text{H}^+$). The enantiopurity was determined to be 88:12 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 215 nm, RT= 24.4 and 28.2 min).




(-)-(3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(2-methylbenzyl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (8r). The general procedure was employed for the coupling of **7c** (61 mg, 0.2 mmol) and 2-bromotoluene (36 μL , 0.3 mmol), using a catalyst composed of Pd_2dba_3 (3.7 mg, 0.004 mmol), and (*S*)-Siphos-PE (8 mg, 0.016 mmol). This procedure afforded 65 mg (82%) of the title compound as a pale brown oil and as a 5:1 mixture of diastereomers as determined by ^1H NMR analysis: $[\alpha]_D^{23} -30.1$ (c 5.7, CH_2Cl_2). Data are for the major isomer. ^1H NMR (700 MHz, CDCl_3) δ 7.36 (d, $J = 9.1$ Hz, 2 H), 7.26 (d, $J = 8.4$ Hz, 2 H), 7.11–7.08 (m, 3 H), 6.93–6.92 (m, 1 H), 5.78–5.71 (m, 1 H), 5.04 (dd, $J = 1.4, 17.5$ Hz, 1 H), 5.01 (dd, $J = 1.4, 10.5$ Hz, 1 H), 4.09 (dt, $J = 4.2, 12.6$ Hz, 1 H), 4.04 (dt, $J = 2.8, 9.1$ Hz, 1 H), 3.86 (ddt, $J = 2.8, 5.6, 11.2$ Hz, 1 H), 2.93 (dd, $J = 3.5, 14.0$ Hz, 1 H), 2.80 (dd, $J = 5.6, 12.6$ Hz, 1 H), 2.62 (dd, $J = 11.2, 14.0$ Hz, 1 H), 2.11–2.02 (m, 3 H), 2.01 (s, 3 H), 1.99–1.94 (m, 1 H), 1.87 (dd, $J = 6.3, 12.6$ Hz, 1 H), 1.65 (ddd, $J = 6.3, 11.2, 17.5$ Hz, 1 H), 1.58 (dt, $J = 5.6, 12.6$ Hz, 1 H); ^{13}C NMR (175 MHz, CDCl_3) δ 153.6, 140.7, 136.3, 135.7, 135.6, 131.5, 130.6, 130.3, 129.6, 129.0, 126.8, 126.0, 117.0, 58.4, 57.5, 52.9, 37.7, 36.8, 30.8, 30.1, 27.8, 19.2; IR (film) 1642 cm^{-1} . MS (ESI)

395.1885 (395.1885 calcd for $C_{24}H_{27}ClN_2O$, $M + H^+$). The enantiopurity was determined to be 71:29 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 215 nm, RT= 20.1 and 24.3 min).

Deprotection of Bicyclic Urea Product 8c




(-)-(Z,3S,4aS,7R)-N-{4-[7-Allyl-1-oxo-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-2(1H)-yl]phenyl}acetamide (S3). A flame-dried screwtop-flask was cooled under vacuum and charged with $Pd_2(dba)_3$ (5.2 mg, 0.006 mmol), 2-di-*tert*-butylphosphino-3,4,5,6-tetramethyl-2',4',6'-triisopropyl-1,1'-biphenyl (13.7 mg, 0.03 mmol), K_3PO_4 (182 mg, 0.86 mmol) and acetamide (50.8 mg, 0.86 mmol). The flask was evacuated and backfilled with N_2 , and then a solution of **8c** (206 mg, 0.57 mmol) in *tert*-butanol (3 mL) was added via syringe. The flask was sealed, heated to 110 °C and stirred overnight (14 h). The mixture was cooled to room temperature and the mixture was filtered through a plug of celite, eluted with EtOAc (10 mL), and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 191 mg (88%) of the title compound as a foamy brown solid: mp = 38–42 °C. $[\alpha]_D^{23}$ -25.2 (*c* 5.3, CH_2Cl_2). 1H NMR (700 MHz, $CDCl_3$) δ 8.93 (s, 1 H), 7.21 (d, J = 8.4 Hz, 2 H), 6.98 (d, J = 8.4 Hz, 2 H), 5.77–5.72 (m, 1 H), 5.49–5.40 (m, 1 H), 5.07–5.03 (m, 3 H), 4.03 (dt, J = 2.8, 9.1 Hz, 1 H), 3.77 (dt, J = 4.2, 10.5 Hz, 1 H), 3.67 (ddt, J = 2.8, 4.9, 8.4 Hz, 1 H), 2.80 (dd, J = 4.9, 12.6 Hz, 1 H), 2.25–2.08 (m, 4 H), 2.05 (s, 3 H) 2.02–1.98 (m, 1 H), 1.95–1.85 (m, 4 H), 1.70–1.64 (m, 2 H), 0.88 (t, J = 7.7 Hz, 3 H); ^{13}C NMR (175 MHz, $CDCl_3$) δ 168.8, 154.5, 137.3, 136.6, 135.5, 134.8, 128.3, 124.0, 121.3, 117.1, 58.5, 57.3, 52.8, 37.8, 31.2, 31.0, 30.8, 27.7, 24.0, 20.8, 14.1; IR (film) 3263, 1687, 1624 cm^{-1} . MS (ESI) 382.2493 (382.2489 calcd for $C_{23}H_{31}N_3O_2$, $M + H^+$).



(-)-(Z,3S,4aS,7R)-7-Allyl-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (9).

A Schlenk tube was charged with a stirbar, **S3** (39 mg, 0.1 mmol) and CH₃CN (1 mL). A solution of ceric ammonium nitrate (164 mg, 0.3 mmol) in H₂O (1 mL) was added to the reaction flask and the mixture was stirred at rt for 5 min. The mixture was then heated at 50 °C for 15 min before being cooled to rt, at which time EtOAc (5 mL) was added. The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was washed with saturated aqueous Na₂SO₃ (5 mL), saturated aqueous NaHCO₃ (5 mL), and brine (5 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography (2% MeOH in CH₂Cl₂) on silica gel to afford 19 mg (77%) of the title compound as a yellow brown solid: $[\alpha]_D^{23} -63.2$ (c 0.5, CH₂Cl₂). ¹H NMR (500 MHz, CDCl₃) δ 5.80–5.72 (m, 1 H), 5.57–5.51 (m, 1 H), 5.30–5.25 (m, 1 H), 5.06–5.02 (m, 2 H), 4.73 (s, 1 H), 4.00 (dt, *J* = 3.0, 8.5 Hz, 1 H), 3.49 (ddt, *J* = 3.0, 5.5, 11.5 Hz, 1 H), 3.46–3.41 (m, 1 H), 2.72 (d, *J* = 14.5 Hz, 1 H), 2.26–2.20 (m, 1 H), 2.13–1.93 (m, 6 H), 1.88–1.77 (m, 2 H), 1.61–1.52 (m, 2 H), 0.96 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 155.1, 135.6, 135.2, 124.0, 117.0, 56.2, 52.9, 50.0, 38.1, 35.7, 32.3, 30.7, 27.4, 20.8, 14.1; IR (film) 3207, 1652 cm⁻¹. MS (ESI) 249.1963 (249.1961 calcd for C₁₅H₂₄N₂O, M + H⁺).


Conversion of Bicyclic Urea Product 8c to Tricyclic Guanidine 12



(-)-(Z,3S,4aS,7R)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-imine hydrochloride (10).

A flame-dried flask was cooled under a stream of N₂ and charged with **8c** (177 mg, 0.49 mmol) and toluene (5 mL). Freshly distilled POCl₃ (2.5 mL, 27 mmol) was added and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 3 hr). The reaction mixture was cooled to rt and concentrated *in vacuo*. The crude product was dissolved in acetonitrile (5 mL) and a solution of


ammonia (20 mL, 2 M in ethanol) was added. The mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 1 hr). The reaction mixture was concentrated and dissolved in methylene chloride (5 mL). Water (5 mL) was added and the mixture was transferred to a separatory funnel. The layers were separated and the organic layer was washed with saturated aqueous NaCl (3 x 10 mL). The combined aqueous layers were extracted with methylene chloride (3 x 10 mL). The combined organics layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 146 mg (75%) of the title compound as a pale white-yellow foam: $[\alpha]_D^{23} -45.5$ (c 1.1, CH₂Cl₂). ¹H NMR (700 MHz, CDCl₃) δ 7.48 (d, *J* = 7.7 Hz, 1 H), 7.40 (d, *J* = 7.7 Hz, 1 H), 7.29 (d, *J* = 7.0 Hz, 1 H), 7.14 (d, *J* = 8.4 Hz, 1 H), 5.96–5.90 (m, 1 H), 5.45 (dt, *J* = 7.0, 10.5 Hz, 1 H), 5.00–4.93 (m, 4 H), 3.75–3.72 (m, 1 H), 3.62–3.58 (m, 1 H), 2.67 (d, *J* = 13.3 Hz, 1 H), 2.25 (dd, *J* = 2.1, 14.0 Hz, 1 H), 2.18–2.16 (m, 1 H) 2.12–2.06 (m, 3 H), 2.03–1.93 (m, 2 H), 1.81–1.68 (m, 4 H), 0.82 (t, *J* = 7.7 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 151.3, 136.6, 136.1, 135.8, 134.5, 131.5, 131.4, 130.8, 128.9, 121.7, 118.3, 59.5, 59.1, 53.1, 36.2, 30.8, 30.4, 29.6, 28.1, 20.8, 13.9; IR (film) 3457, 3275, 1636 cm⁻¹. MS (ESI) 358.2048 (358.2045 calcd for C₂₁H₂₉ClN₃, M⁺).



(-)-(Z,2aS,4S,7S,8aR)-5-(4-Chlorophenyl)-7-methyl-4-(pent-2-en-1-yl)-1,2,2a,3,4,5,6,7,8,8a-decahydro-2a¹,5,6-triazaacenaphthylene-2a¹-ium chloride (12). A test tube was charged with **10** (39.4 mg, 0.1 mmol), PdCl₂ (3.5 mg, 0.02 mmol), and CuCl (14.8 mg, 0.15 mmol). The tube was capped with a rubber septum, was briefly flushed with oxygen and then an oxygen-filled balloon attached to a needle (via an adaptor) was connected to the tube through the septum. A solution of THF and H₂O (7:1, 1.0 mL) was added to the test tube and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 4 hr). Methanol (1 mL) and NaCNBH₃ (62.8 mg, 1.0 mmol) was added and the mixture was heated to 50 °C until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 3 hr). The reaction mixture was cooled to rt and concentrated *in vacuo*. The crude product was dissolved in methylene chloride (20 mL), the mixture was transferred to a separatory funnel and


2 M HCl (10 mL) was added. The layers were separated and the organic layer was washed with NH₄OH (10 mL) to potentially remove any excess copper. The layers were separated and the organic layer was washed with 2 M HCl (10 mL). The organics layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 31 mg (79%) of the title compound as a pale white-tan oil and as a 5:1 mixture of diastereomers as determined by ¹H NMR analysis: [α]_D²³ -38.1 (c 0.6, CH₂Cl₂). Data are for the major isomer. ¹H NMR (500 MHz, CDCl₃) δ 7.56 (d, *J* = 7.5 Hz, 2 H), 7.34 (d, *J* = 8.5 Hz, 2 H), 5.57–5.52 (m, 1 H), 5.10–5.05 (m, 1 H), 4.64 (s, 1 H), 3.99–3.90 (m, 2 H), 3.77–3.73 (m, 1 H), 3.69–3.65 (m, 1 H), 2.46–2.32 (m, 5 H), 2.28 (dt, *J* = 3.5, 13.0 Hz, 1 H), 1.99–1.93 (m, 3 H), 1.88–1.80 (m, 2 H), 1.51–1.44 (m, 1 H), 1.22 (d, *J* = 6.5 Hz, 3 H), 0.93 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 148.6, 136.6, 136.5, 135.2, 132.0–129.0 (br, 2 C), 121.9, 59.8, 57.7, 52.1, 47.4, 34.8, 30.0, 29.9, 29.6, 29.4, 20.9, 20.6, 14.0; IR (film) 3276, 1607 cm⁻¹. MS (ESI) 358.2047 (358.2045 calcd for C₂₁H₂₉ClN₃, M⁺).

Conversion of Bicyclic Urea Product 8c to 9-*epi*-Batzelladine K 16



(-)-(Z,3S,4aS,7R)-N-{4-[1-Oxo-7-(2-oxopropyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-2(1H)-yl]phenyl}acetamide (13). A test tube was charged with **S3** (300 mg, 0.79 mmol), PdCl₂ (28 mg, 0.16 mmol), and CuCl (117 mg, 1.18 mmol). The tube was capped with a rubber septum, was briefly flushed with oxygen and then an oxygen-filled balloon attached to a needle (via an adaptor) was connected to the tube through the septum. A solution of DMF and H₂O (7:1, 8.0 mL) was added to the test tube and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 4 hr). EtOAc (20 mL) and brine (20 mL) was added and the mixture was transferred to a separatory funnel. The layers were separated and the organic layer was washed with NH₄OH (5 mL) to potentially remove any excess copper. The combined aqueous layers were then extracted with EtOAc (20 mL). The organics layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*.


The crude material was purified by flash chromatography on silica gel to afford 230 mg (74%) of the title compound as a pale yellow-pink solid: mp = 68–72 °C. $[\alpha]_D^{23}$ –38.8 (c 0.8, CH₂Cl₂). ¹H NMR (700 MHz, CDCl₃) δ 8.66 (s, 1 H), 7.25 (d, *J* = 8.4 Hz, 2 H), 7.01 (d, *J* = 9.1 Hz, 2 H), 5.44–5.41 (m, 1 H), 5.06–5.03 (m, 1 H), 4.37–4.34 (m, 1 H), 3.80–3.77 (m, 1 H), 3.66 (ddd, *J* = 2.8, 4.9, 11.2 Hz, 1 H), 3.44 (dd, *J* = 2.8, 9.8 Hz, 1 H), 2.31 (dd, *J* = 9.8, 16.8 Hz, 1 H), 2.26–2.13 (m, 3 H), 2.10 (s, 3 H), 2.06 (s, 3 H), 2.09–2.03 (m, 2 H), 1.91–1.86 (m, 2 H), 1.77 (dd, *J* = 7.0, 13.3 Hz, 1 H), 1.65–1.58 (m, 2 H), 0.88 (t, *J* = 7.0 Hz, 3 H); ¹³C NMR (175 MHz, CDCl₃) δ 207.5, 168.7, 154.2, 137.2, 136.7, 134.9, 128.3, 123.8, 121.1, 58.5, 53.7, 52.8, 47.6, 31.1, 30.8, 30.2, 29.4, 24.0, 20.8, 14.0 (one carbon signal is absent due to incidental equivalence); IR (film) 3261, 1711, 1687, 1621 cm⁻¹. MS (ESI) 398.2439 (398.2438 calcd for C₂₃H₃₁N₃O₃, M + H⁺).



(–)-(3S,4aS,7R)-7-(2-Oxopropyl)-3-pentylhexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (14).

A flame-dried flask was cooled under vacuum and charged with **13** (100 mg, 0.25 mmol) and Pd/C (10 mg). The flask was capped with a rubber septum, was briefly flushed with hydrogen and then a hydrogen-filled balloon attached to a needle (via an adaptor) was connected to the flask through the septum. Methanol (2.5 mL) was added to the flask and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 45 min). The crude product was then filtered through a plug of celite to remove the Pd/C and washed with methanol (5 mL). The crude material was concentrated *in vacuo* and carried on to the next step without further purification. The crude product was dissolved in CH₃CN (10 mL) and transferred to a round-bottom flask charged with a stirbar. A solution of ceric ammonium nitrate (123 mg, 0.75 mmol) in H₂O (30 mL) was added to the reaction flask and the mixture was stirred at rt for 5 min. The mixture was then heated at 50 °C for 4 hr before being cooled to rt, at which time EtOAc (25 mL) was added. The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was washed with saturated aqueous Na₂SO₃ (15 mL), saturated aqueous NaHCO₃ (15 mL), and brine (15 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 34 mg (51%) of the title compound as a white solid: mp = 84–88 °C. $[\alpha]_D^{23}$ –11.7 (c 2.5, CH₂Cl₂). ¹H NMR (700 MHz, CDCl₃) δ 4.79 (s, 1 H), 4.30–4.28 (m, 1 H), 3.48–3.45 (m, 1 H), 3.43–3.39 (m, 2 H), 2.29 (dd, *J* = 9.8, 16.8 Hz, 1 H),

2.10 (s, 3 H), 2.03–1.98 (m, 2 H), 1.95–1.94 (m, 1 H), 1.72 (dd, $J = 7.7, 12.6$ Hz, 1 H), 1.54–1.46 (m, 3 H), 1.38–1.25 (m, 7 H), 0.88 (t, $J = 7.0$ Hz, 3 H); ^{13}C NMR (175 MHz, CDCl_3) δ 207.7, 155.0, 52.8, 52.8, 50.0, 47.6, 37.8, 32.9, 31.6, 30.6, 30.3, 29.0, 25.5, 22.6, 14.0; IR (film) 3207, 1709, 1649 cm^{-1} . MS (ESI) 267.2065 (267.2067 calcd for $\text{C}_{15}\text{H}_{26}\text{N}_2\text{O}_2$, $\text{M} + \text{H}^+$).




(-)-9-epi-Batzelladine K (16). A flame-dried flask was cooled under vacuum and charged with **14** (25 mg, 0.09 mmol) and dichloromethane (0.9 mL). 2,6-di-*tert*-butylpyridine (203 μL , 0.94 mmol) and MeOTf (103 μL , 0.94 mmol) were added and the mixture was stirred at rt until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 1 hr). The solvent was then removed in a hood by blowing a constant stream of N_2 over the stirring mixture. The solution was then poured in diethyl ether (20 ml) and washed with 1 M NaOH (10 mL) and brine (10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was used without further purification. The crude *O*-methylisourea was dissolved in methanol (2 mL) and transferred to a thick walled glass vial at which time ammonium chloride (10.1mg, 0.19 mmol) was added to this solution. Anhydrous ammonia was bubbled through this solution for ~15 min before the reaction vessel was sealed and heated to 60 °C overnight (14 hr). The reaction was cooled to rt and concentrated *in vacuo*. The crude guanidine product **15** was used without further purification. Crude product **15** was dissolved in methanol (3 mL), NaCNBH_3 (59 mg, 0.94 mmol) was added and the mixture was heated to 50 °C until the starting material had been consumed as judged by ESI⁺ MS analysis (ca. 12 hr). The reaction mixture was cooled to rt and concentrated *in vacuo*. The crude product was dissolved in methylene chloride (20 mL), the mixture was transferred to a separatory funnel and washed with 2 M HCl (2 x 10 mL) and brine (1 x 10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was determined to be a 3:1 mixture of diastereomers by ^1H NMR analysis. The crude material was purified by flash chromatography on silica gel to afford 13 mg (48%) of the title compound as a pale yellow oil. The following data is for the pure isolated major diastereomer. $[\alpha]_{\text{D}}^{23} -43.8$ (c 0.5, CH_2Cl_2). ^1H NMR (700 MHz, CDCl_3) δ 3.80–3.73 (m, 2 H), 3.58–3.53 (m, 1 H), 3.52–3.49 (m, 1 H), 2.26–2.21 (m, 3 H), 2.19 (dd, $J = 4.2, 13.3$ Hz, 1 H), 1.73–1.64 (m, 2 H), 1.60–1.56 (m, 2 H), 1.52–1.47 (m, 1 H), 1.44–1.27 (m, 7 H), 1.27 (d, $J = 6.3$ Hz, 3 H), 0.93 (t, $J = 7.0$ Hz, 3 H);


^{13}C NMR (175 MHz, CDCl_3) δ 149.4, 56.3, 51.6, 48.4, 45.8, 36.2, 35.5, 31.5, 31.2, 30.5, 30.2, 25.5, 22.4, 20.5, 14.0; ^1H NMR (700 MHz, CD_3OD) δ 7.56 (d, $J = 7.5$ Hz, 2 H), 7.34 (d, $J = 8.5$ Hz, 2 H), 5.57–5.52 (m, 1 H), 5.10–5.05 (m, 1 H), 4.64 (s, 1 H), 3.99–3.90 (m, 2 H), 3.77–3.73 (m, 1 H), 3.69–3.65 (m, 1 H), 2.46–2.32 (m, 5 H), 2.28 (dt, $J = 3.5, 13.0$ Hz, 1 H), 1.99–1.93 (m, 3 H), 1.88–1.80 (m, 2 H), 1.51–1.44 (m, 1 H), 1.22 (d, $J = 6.5$ Hz, 3 H), 0.93 (t, $J = 7.5$ Hz, 3 H); ^{13}C NMR (175 MHz, CD_3OD) δ 150.4, 57.5, 53.5, 50.2, 47.3, 36.8, 36.1, 32.7, 31.9, 31.3, 30.7, 26.8, 23.6, 20.8, 14.3; IR (film) 3284, 3202, 1637 cm^{-1} . MS (ESI) 250.2278 (250.2278 calcd for $\text{C}_{15}\text{H}_{28}\text{N}_3$, M^+).

Assignment of Stereochemistry

The relative stereochemistry of compound **8k** was assigned on the basis of observed ^1H NMR nOe experiments. Significant nOe relationships are shown below. The stereochemistry of all other bicyclic urea products was assigned based on analogy to **8k**.





The relative stereochemistry of compounds **12** and **16** were assigned on the basis of observed ^1H NMR nOe experiments. Significant nOe relationships are shown below.



The absolute stereochemistry of the urea products was assigned via the synthesis of compound **ent-8c** from pent-4-enal via the route illustrated below in Scheme S1. The optical rotation of product **ent-8c** prepared via this route was opposite that of the product **8c** generated in the Pd-catalyzed carboamination reaction between **7c** and Z-bromobutene. In addition, analysis of


product **ent-8c** by chiral HPLC indicated that **ent-8c** was the enantiomer of product **8c** formed in the catalytic reaction.

Scheme S1




(-)-(R_S)-2-Methyl-N-(pent-4-en-1-ylidene)propane-2-sulfonamide (S4). This compound was prepared according to the procedure reported by Ellman.^[4] A flame-dried flask was cooled under a stream of N₂ and charged with pent-4-enal (1.38 mL, 14 mmol) and THF (40 mL). Titanium ethoxide (4.2 mL, 20 mmol) was added and the reaction mixture was stirred at rt for 5 min. (*R*)-*tert*-butanesulfonamide (1.21 g, 10 mmol) was added in one portion and the mixture was stirred overnight (ca. 14 h) at rt. The reaction mixture was poured into brine (40 mL) and stirred for 10 min. Ethyl acetate (20 mL) was added, the mixture was filtered through celite and the celite was washed with ethyl acetate (50 mL). The mixture was transferred to a separatory funnel, brine (20 mL) was added, and the layers were separated. The aqueous phase was extracted with ethyl acetate (2 x 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 1.38 g (74%) of the title compound as a colorless oil. Spectroscopic properties are identical to those previously reported.^[5] ¹H NMR (500 MHz, CDCl₃)

δ 8.08 (t, $J = 4.5$ Hz, 1 H), 5.84 (ddt, $J = 4.5, 10.0, 17.0$ Hz, 1 H), 5.08 (dd, $J = 1.5, 17.0$ Hz, 1 H), 5.02 (dd, $J = 1.5, 10.0$ Hz, 1 H), 2.63 (td, $J = 4.0, 7.5$ Hz, 2 H), 2.40 (q, $J = 7.0$ Hz, 2 H), 1.19 (s, 9 H).




($R_S, 4R$)-2-Methyl- N -(octa-1,7-dien-4-yl)propane-2-sulfonamide (S5**).** A flame-dried flask was cooled under a stream of N_2 and charged with freshly ground magnesium turnings (720 mg, 4 equiv). The magnesium was suspended in ether (14.8 mL, 1 M), cooled to 0 °C in an ice/water bath and allyl bromide (1.28 mL, 14.8 mmol) was added dropwise. After addition, the ice bath was removed, and the reaction mixture was stirred at rt for 30 min. Stirring was stopped and the solution was filtered through glass wool prior to addition to **S4**. A flame-dried flask was cooled under a stream of N_2 and charged with **S4** (1.38 g, 7.4 mmol) and THF (37 mL, 0.2 M). The sulfinyl imine solution was cooled to 0 °C in an ice/water bath before the filtered Grignard reagent solution was added dropwise. The reaction mixture was stirred at 0 °C until the starting material had been completely consumed as judged by TLC analysis (1 h). Water was then added dropwise until precipitation of magnesium salts occurred and the resulting solution was decanted into a separate flask. The solution was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. Analysis of the crude product by 1H NMR indicated that a 10:1 mixture of diastereomers had formed. The crude material was purified by flash chromatography on silica gel to afford 1.02 g (60%) of the title compound as a 10:1 mixture of diastereomers as a clear colorless oil. Data are for the major isomer. 1H NMR (500 MHz, $CDCl_3$) δ 5.83–5.74 (m, 2 H), 5.18–4.97 (m, 4 H), 3.36–3.32 (m, 1 H), 3.21 (d, $J = 6.5$ Hz, 1 H), 2.45–2.40 (m, 1 H), 2.37–2.32 (m, 1 H), 2.18–2.08 (m, 2 H), 1.62–1.58 (m, 2 H), 1.21 (s, 9 H).




(R)-tert-Butyl octa-1,7-dien-4-ylcarbamate (S1**).** A flame-dried flask was cooled under a stream of N_2 and charged with **S5** (1.02 g, 4.4 mmol) and methanol (22 mL). A solution of anhydrous hydrochloric acid (4.4 mL, 17.7 mmol, 4 M in dioxane) was added and the mixture was stirred at rt for 1 h, at which time TLC analysis indicated that the starting material had been

completely consumed. The reaction mixture was diluted with water (10 mL) and CH₂Cl₂ (10 mL), basified with NH₄OH to pH > 12, and transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with CH₂Cl₂ (3 x 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude product was dissolved in THF (44 mL, 0.1 M), solid di-*tert*-butyldicarbonate (1.2 g, 5.3 mmol) was added and the reaction mixture was stirred at rt for 3 h. 1 M NaOH (5 mL) was added and the resulting biphasic mixture was stirred for 1 h at rt. The mixture was transferred to a separatory funnel, the layers were separated and the aqueous layer was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 941 mg (94%) of the title compound as a clear colorless oil. The spectroscopic properties of this compound were identical to that of compound (\pm)-**S1** described above.




(*E,2R,5S*)-*tert*-Butyl 2-allyl-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxylate (S2**)**. A flame-dried Schlenk flask was cooled under a stream of N₂ and charged with Pd₂(dba)₃ (77 mg, 0.084 mmol), tri(2-furyl)phosphine (77 mg, 0.33 mmol) and NaOtBu (802 mg, 8.4 mmol). The flask was purged with N₂, then a solution of (**R**)-**S1** (941 mg, 4.2 mmol) in freshly distilled xylenes (21 mL) was added via syringe and the resulting mixture was stirred at rt for 2 min. (*E*)-(2-bromovinyl)trimethylsilane (1.28 mL, 8.4 mmol) was added and the flask was heated to 140 °C and stirred for 3 h. The mixture was cooled to room temperature and saturated aqueous NH₄Cl (10 mL) and ethyl acetate (10 mL) were added. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (20 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 647 g (48%) of the title compound as a dark brown oil. The spectroscopic properties of this compound were identical to that of compound (\pm)-**S2** described above.



(E,2R,5S)-2-Allyl-N-(4-chlorophenyl)-5-[3-(trimethylsilyl)allyl]pyrrolidine-1-carboxamide


(S6). A round-bottom flask equipped with a stirbar was charged with **(E,2R,5S)-S2** (647 mg, 2.0 mmol) and dichloromethane (20 mL, 0.1 M). Trifluoroacetic acid (2.0 mL, 1.0 M) was added to the flask and the mixture was stirred for 20 min at rt. The solution was diluted with water, basified with NH_4OH to $\text{pH} > 12$, and transferred to a separatory funnel. The layers were separated and the aqueous layer was extracted with CH_2Cl_2 (3 x 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude product was dissolved in dichloromethane (20 mL, 0.1 M) and 4-chlorophenyl isocyanate (369 mg, 1.2 equiv) was added. The reaction mixture was stirred at rt for 1 h until starting material had been completely consumed as judged by TLC analysis. The crude reaction mixture was concentrated *in vacuo*, and purified by flash chromatography on silica gel to afford 244 mg (32%) of the title compound as a orange brown oil. ^1H NMR (500 MHz, CDCl_3) δ 7.31 (d, $J = 9.0$ Hz, 2 H), 7.22 (d, $J = 9.0$ Hz, 2 H), 6.41 (s, 1 H), 6.04 (dt, $J = 7.0, 18.5$ Hz, 1 H), 5.93–5.84 (m, 1 H), 5.82 (d, $J = 18.5$ Hz, 1 H), 5.22–5.17 (m, 2 H), 4.02–3.95 (m, 2 H), 2.61–2.52 (m, 2 H), 2.35 (dt, $J = 7.0, 13.5$ Hz, 1 H), 2.24 (dt, $J = 7.5, 14.0$ Hz, 1 H), 2.02–1.96 (m, 2 H), 1.80–1.74 (m, 2 H), 0.05 (s, 9 H).



(E,Z,3R,4aR,7S)-2-(4-Chlorophenyl)-3-(pent-2-en-1-yl)-7-[3-

(trimethylsilyl)allyl]hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (S7). A flame-dried Schlenk tube was cooled under vacuum and charged with $\text{Pd}_2(\text{dba})_3$ (3.1 mg, 0.003 mmol), $\text{PCy}_3\cdot\text{HBF}_4$ (5.0 mg, 0.014 mmol) and NaOtBu (25 mg, 0.26 mmol). The flask was evacuated and purged with N_2 . A solution of **S6** (65 mg, 0.17 mmol) in toluene (0.85 mL) was added via syringe and

the resulting mixture was stirred at rt for 2 min. (Z)-1-bromobut-1-ene (130 μ L, 0.26 mmol, 2.0 M solution in toluene) was added and the tube was heated to 100 $^{\circ}$ C and stirred until the starting material was completely consumed as judged by TLC analysis (1 h). The mixture was cooled to room temperature and saturated aqueous NH_4Cl (1 mL) and ethyl acetate (1 mL) were added. The layers were separated, the organic layer was filtered through a plug of silica gel, and the silica gel was washed with ethyl acetate (1 mL). The filtrate was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel to afford 53 mg (71%) of the title compound as a yellow oil. ^1H NMR (500 MHz, CDCl_3) δ 7.31 (d, J = 9.0 Hz, 2 H), 7.19 (d, J = 9.0 Hz, 2 H), 5.94 (ddd, J = 6.0, 7.5, 18.5 Hz, 1 H), 5.68 (d, J = 18.5 Hz, 1 H), 5.47–5.42 (m, 1 H), 5.12–5.07 (m, 1 H), 4.03 (dt, J = 2.5, 8.5 Hz, 1 H), 3.90 (dt, J = 4.5, 9.5 Hz, 1 H), 3.66 (ddt, J = 2.5, 5.0, 11.5 Hz, 1 H), 2.73 (dd, J = 5.5, 12.5 Hz, 1 H), 2.27–2.16 (m, 4 H), 2.01–1.89 (m, 4 H), 1.84–1.81 (m, 1 H), 1.69–1.61 (m, 2 H), 0.90 (t, J = 7.5 Hz, 3 H), 0.03 (s, 9 H).





(+)-(Z,3R,4aR,7S)-7-Allyl-2-(4-chlorophenyl)-3-(pent-2-en-1-yl)hexahydropyrrolo[1,2-c]pyrimidin-1(2H)-one (*ent*-8c). A Schlenk tube was charged with **S7** (53 mg, 0.12 mmol) and CH_2Cl_2 (1.2 mL). TFA (0.6 mL) was added and the reaction mixture was stirred overnight at 40 $^{\circ}$ C. The reaction mixture was then cooled to rt, diluted with water (1 mL), and basified with NH_4OH to pH > 12. The reaction mixture was transferred to a separatory funnel and the layers were separated. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo*. The crude material was purified by flash chromatography on silica gel. This procedure afforded 29 mg (67%) of the title compound as a yellow oil: $[\alpha]_D^{23} +17.7$ (c 2.9, CH_2Cl_2). The spectroscopic properties of this compound were identical to that of compound **8c**. The enantiopurity was determined to be 10:90 er by chiral HPLC analysis (chiralcel ADH, 25 cm x 4.6 mm, 5% IPA/Hexanes, 0.75 mL/min, λ 190 nm, RT= 13.4 and 17.8 min).

References

- [1] H. Harada, R. K. Thalji, R. G. Bergman, J. A. Ellman, *J. Org. Chem.* **2008**, *73*, 6772–6779.
- [2] S. Hanessian, A. Tehim, P. Chen, *J. Org. Chem.* **1993**, *58*, 7768–7781.
- [3] S. J. Veenstra, P. Schmid, *Tetrahedron Lett.* **1997**, *38*, 997–1000.
- [4] G. Liu, D. A. Cogan, T. D. Owens, T. P. Tang, J. A. Ellman, *J. Org. Chem.* **1999**, *64*, 1278–1284.
- [5] N. R. Babij, J. P. Wolfe, *Angew. Chem.* **2012**, *124*, 4204–4206; *Angew. Chem. Int. Ed.* **2012**, *51*, 4128–4130.


Sample Name:
Data Collected on:
Sn.Chem.LSA.UMich.edu-inova500
Archive directory:
Sample directory:
FidFile: NRB-4-1-1H
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Sep 26 2012


Agilent Technologies



Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-1-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Sep 27 2012


Agilent Technologies






Sample Name:
 Data Collected on:
 Sn.Chem.LSA.UMich.edu-inova900
 Archive directory:
 Sample directory:
 FidFile: NRB-4-88-1H
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Sep 22 2012

Agilent Technologies





Sample Name:
 Data Collected on:
 Sn.Chem.LSA.UMich.edu-inova500
 Archive directory:
 Sample directory:
 FidFile: NRB-4-88-13C
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Sep 22 2012

Agilent Technologies




Sample Name:
Data Collected on:
Yb-vnars700
Archive directory:
Sample directory:
FidFile: NRB-4-100-A-1H
Pulse Sequence: PROTON (s2pu1)
Solvent: cdcl3
Data collected on: Oct 16 2012





Sample Name:
Data Collected on:
Yb-vnars700
Archive directory:
Sample directory:
FidFile: NRB-4-100-A-13C
Pulse Sequence: CARBON (s2pu1)
Solvent: cdcl3
Data collected on: Oct 16 2012


Agilent Technologies





Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-100-B-1H
 Pulse Sequence: PROTON (s2pu1)
 Solvent: cdcl3
 Data collected on: Oct 16 2012



Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-100-B-13C
 Pulse Sequence: CARBON (s2pu1)
 Solvent: cdcl3
 Data collected on: Oct 16 2012




Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-135-sm
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Dec 21 2012




Sample Name:
Data Collected on:
Sn_Chem_15A_UMich.edu-inova500
Archive directory:
Sample directory:
FidFile: NRB-4-79-sm-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Sep 12 2012

Agilent Technologies




Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-100-C
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Oct 16 2012

Agilent Technologies




7d





Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-100-C-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Oct 16 2012

Agilent Technologies




Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-100-D-1H
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Oct 16 2012





Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-100-D-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Oct 16 2012

Agilent Technologies




Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-100-E-1H
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Oct 16 2012





Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-100-E-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Oct 16 2012

Agilent Technologies




Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-22-X-1H
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Oct 18 2012



Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-22-X-13C
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Oct 18 2012


Agilent Technologies



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\IRACEMIC-NRB-4-11-PMP-Z-BUTENE-100-ADH-2.5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-11-PMP-Z-BUTENE-100-ADH-2.5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-11-PMP-Z-BUTENE-100-ADH-2.5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/24/2012 1:59:11 PM
 Data Processed : 10/24/2012 2:54:56 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	44.346	12121126	126849	51.297
2	48.073	11508366	99562	48.703
Total		23629492	226411	100.000



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-11-PMP-Z-BUTENE-90-SSIPHOSPE-ADH-2.5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-11-PMP-Z-BUTENE-90-SSIPHOSP-ADH-2.5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-11-PMP-Z-BUTENE-90-SSIPHOSPE-ADH-2.5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 5/2/2012 6:06:42 PM
 Data Processed : 5/2/2012 7:02:07 PM

<Chromatogram>





PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	44.237	12187752	106584	86.224
2	49.097	1947258	15346	13.776
Total		14135011	121931	100.000



Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-101-X-1H
 Pulse Sequence: PROTON (s2pu1)
 Solvent: cdcl3
 Data collected on: Oct 18 2012




Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-101-X-13C
 Pulse Sequence: CARBON (s2pu1)
 Solvent: cdcl3
 Data collected on: Oct 18 2012



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-101-34PMP-Z-BUTENE-100-PCY3-ADH-5%IPA-0.75ml.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-101-3,4PMP-Z-Butene-100C-ADH-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-101-34PMP-Z-BUTENE-100-PCY3-ADH-5%IPA-0.75ml.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/17/2012 3:45:42 PM
 Data Processed : 10/17/2012 4:18:20 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	21.169	34368966	550494	49.582
2	24.035	34947914	487647	50.418
Total		69316880	1038141	100.000



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-101-34PMP-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-101-34PMP-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-101-34PMP-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/17/2012 9:55:54 PM
 Data Processed : 10/17/2012 10:28:13 PM



<Chromatogram>



PeakTable

Peak#	Ret. Time	Area	Height	Area %	Height %
1	20.395	81981175	1343363	81.873	84.618
2	23.463	18150993	244195	18.127	15.382
Total		100132168	1587557	100.000	100.000






==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-95-pCl-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-95-pCl-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-95-pCl-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/10/2012 3:40:20 PM
 Data Processed : 10/10/2012 4:01:04 PM

<Chromatogram>



PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	13.356	10978832	430437	50.161
2	18.045	10908139	295015	49.839
Total		21886971	725452	100.000




8c

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-118-pCl-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-118-pCl-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-118-pCl-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 11/30/2012 12:32:03 PM
 Data Processed : 11/30/2012 1:30:42 PM


<Chromatogram>



1 PDA Multi 1/190nm 4nm

PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	13.363	40981053	1771633	94.402
2	18.080	2430175	83915	5.598
Total		43411228	1855548	100.000




8c

==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABIJIELLMAN-NRB-4-133-2-pCl-Zbutene--5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : ELLMAN-NRB-4-133-2-pCl-Zbutene--5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : ELLMAN-NRB-4-133-2-pCl-Zbutene--5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 12/18/2012 11:59:32 AM
 Data Processed : 12/18/2012 12:39:48 PM

<Chromatogram>





PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	13.351	1900239	77384	9.636
2	17.847	17820385	506100	90.364
Total		19720624	583483	100.000




ent-8c

Sample Name:
 Data Collected on:
 Yb-vmars700
 Archive directory:
 Sample directory:
 FidFile: PROTON
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Oct 20 2012




Sample Name:
 Data Collected on:
 Yb-vmars700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-103-13C
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Oct 20 2012



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABIJRACEMIC-NRB-4-74-pBr-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-74-pBr-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-74-pBr-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 8/28/2012 6:58:36 PM
 Data Processed : 8/28/2012 7:25:17 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	14.517	154799302	3681642	49.793
2	19.163	156088664	2926638	50.207
Total		310887966	6608280	100.000



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIURAL-NRB-4-74-pBr-Z-BUTENE-100-SIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIURAL-NRB-4-74-pBr-Z-BUTENE-100-SIPHOSPE-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIURAL-NRB-4-74-pBr-Z-BUTENE-100-SIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 8/28/2012 7:28:02 PM
 Data Processed : 10/19/2012 7:38:06 PM

<Chromatogram>





PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	14.528	32443013	1090281	94.464
2	20.017	1901139	49794	5.536
Total		34344152	1140076	100.000




Sample Name:
Data Collected on:
Yb-vnms700
Archive directory:
Sample directory:
FidFile: NRB-4-102-X-1R
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Oct 19 2012

Agilent Technologies



Sample Name:
Data Collected on:
Yb-vnms700
Archive directory:
Sample directory:
FidFile: NRB-4-102-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Oct 18 2012


Agilent Technologies



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-102-pCN-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-102-pCN-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-102-pCN-Z-BUTENE-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/17/2012 4:27:14 PM
 Data Processed : 10/17/2012 5:22:38 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	33.091	38677775	559423	50.478
2	41.446	37945343	343252	49.522
Total		76623118	902676	100.000



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-102-2-pCN-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-102-2-pCN-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-102-2-pCN-Z-BUTENE-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/23/2012 6:10:26 PM
 Data Processed : 10/23/2012 7:08:32 PM

<Chromatogram>





PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	33.160	57259672	784638	94.609
2	42.857	3262654	31536	5.391
Total		60522326	816174	100.000




Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-106-1H
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Oct 31 2012



Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-106-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Oct 30 2012


Agilent Technologies



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\IRACEMIC-NRB-4-106-2-pNO2-Z-BUTENE-120-SSIPHOSPE-5%IPA-1.5ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-106-2-pNO2-Z-BUTENE-120-SSIPHOSPE-5%IPA-1.5ml
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-106-2-pNO2-Z-BUTENE-120-SSIPHOSPE-5%IPA-1.5ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/30/2012 4:06:25 PM
 Data Processed : 10/30/2012 4:40:18 PM

<Chromatogram>



PeakTable

PDA Ch1 310nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	19.256	10775717	217860	49.820
2	25.832	10853467	168010	50.180
Total		21629184	385871	100.000




8f

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-106-pNO2-Z-BUTENE-120-NaOtBu-SSIPHOSPE-5%IPA-1.5ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-106-pNO2-Z-BUTENE-120-NaOtBu-SSIPHOSPE-5%IPA-1.5ml
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-106-pNO2-Z-BUTENE-120-NaOtBu-SSIPHOSPE-5%IPA-1.5ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/30/2012 2:49:31 PM
 Data Processed : 10/30/2012 3:23:55 PM

<Chromatogram>




1 PDA Multi 1/310nm 4nm

PeakTable



PDA Ch1 310nm 4nm

Peak#	Ret. Time	Area	Height	Area %
1	19.106	10898189	210578	96.308
2	26.193	417817	6715	3.692
Total		11316006	217293	100.000



8f


Sample Name:
 Data Collected on:
 Sn.Chem.LSA.UMich.edu-inova500
 Archive directory:
 Sample directory:
 FidFile: NRB-4-140-X-1H-Ehexene
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Jan 24 2013



STANDARD PROTON PARAMETERS

Sample Name:
 Data Collected on:
 Te-vnmrs500
 Archive directory:
 Sample directory:
 FidFile: NRB-4-140-X-13C
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Jan 6 2013


Agilent Technologies



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\IRACEMIC-NRB-4-140-pCl-Ehexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-140-pCl-Ehexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-140-pCl-Ehexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 1/4/2013 4:14:52 PM
 Data Processed : 1/4/2013 4:58:59 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	20.727	13698615	239789	50.749
2	37.695	13294427	136862	49.251
Total		26993042	376651	100.000



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-140-X-2-pCl-Ehexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-140-X-2-pCl-Ehexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-140-X-2-pCl-Ehexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 1/4/2013 4:59:58 PM
 Data Processed : 1/4/2013 5:42:12 PM

<Chromatogram>





PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	19.956	18822079	322958	95.508
2	37.471	885292	10642	4.492
Total		19707371	333600	100.000




Sample Name:
Data Collected on:
Sn.Chem.LSA.UMich.edu-inova500
Archive directory:
Sample directory:
FidFile: NRB-4-141-X-2-hexene-1H
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Jan 24 2013



Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-141-X-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Jan 8 2013


Agilent Technologies



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-141-R-pCl-Zhexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-141-R-pCl-Zhexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_m
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-141-R-pCl-Zhexene-100-NaOtBu-PCy3-1.5%IPA-1.5ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 1/8/2013 12:32:09 PM
 Data Processed : 1/8/2013 1:30:14 PM

<Chromatogram>



PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	20.055	27108175	474557	50.964
2	33.734	26082514	222410	49.036
Total		53190689	696967	100.000




==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-141-X-pCl-Zhexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-141-X-pCl-Zhexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-141-X-pCl-Zhexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 1/7/2013 5:02:46 PM
 Data Processed : 1/7/2013 5:47:55 PM

<Chromatogram>


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-141-X-pCl-Zhexene-100-NaOtBu-SSIPHOSPE-1.5%IPA-1.5ml_min.lcd
 mAU



1 PDA Multi 1/254nm 4nm



PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	20.939	5164727	95174	93.561
2	36.238	355461	4348	6.439
Total		5520188	99522	100.000




8h

Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-134-X-1H
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Dec 19 2012



Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-134-X-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Dec 19 2012


Agilent Technologies




==== Shimadzu LCsolution Analysis Report ====

C:\...\Data\BABI\CHIRAL-NRB-4-123-pCl-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-123-pCl-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-123-pCl-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 12/11/2012 6:02:30 PM
 Data Processed : 12/11/2012 6:43:19 PM

<Chromatogram>




PeakTable				
Peak#	Ret. Time	Area	Height	Area %
1	14.325	16086664	615989	50.923
2	23.320	15503816	317951	49.077
Total		31590479	933941	100.000




==== Shimadzu LCsolution Analysis Report ====

C:\...\Data\BABI\CHIRAL-NRB-4-134-X-pCl-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-134-X-pCl-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-134-X-pCl-1Br2MePropene-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 12/19/2012 3:20:33 PM
 Data Processed : 12/19/2012 3:51:53 PM

<Chromatogram>





PeakTable				
Peak#	Ret. Time	Area	Height	Area %
1	13.819	40943767	1527198	93.771
2	23.975	2719612	58406	6.229
Total		43663379	1585604	100.000



8i


Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-135-X-1H-2propene
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Dec 21 2012



STANDARD PROTON PARAMETERS

Sample Name:
 Data Collected on:
 Te-vnmrs500
 Archive directory:
 Sample directory:
 FidFile: NRB-4-135-X-13C-2propene
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Dec 21 2012






==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-126-2-pCl-2Propene-100-PCY3-3%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-126-2-pCl-2Propene-100-PCY3-3%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-126-2-pCl-2Propene-100-PCY3-3%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 12/20/2012 1:52:01 PM
 Data Processed : 12/20/2012 2:31:47 PM

<Chromatogram>



PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	23.235	26432880	621250	49.297
2	28.496	27186656	434267	50.703
Total		53619536	1055517	100.000




8j

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-135-2-pCl-2propene-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-135-2-pCl-2prop-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-135-2-pCl-2propene-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 12/20/2012 5:22:09 PM
 Data Processed : 12/20/2012 6:22:39 PM


<Chromatogram>

C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-135-2-pCl-2propene-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd
 mAU





PeakTable

PDA Ch1 254nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	22.761	6535743	152637	88.459
2	28.377	852687	14946	11.541
Total		7388431	167583	100.000




8j

Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-105-X-A-1H-tolyl
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Oct 25 2012




Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-105-X-A-13C-tolyl
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Oct 25 2012


Agilent Technologies




Sample Name:
 Data Collected on:
 Yb-vmars700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-120-COSY-4tol
 Pulse Sequence: gCOSY
 Solvent: cdcl3
 Data collected on: Dec 10 2012
 Operator: nbabij
 Relax. delay 1.000 sec
 Acq. time 0.150 sec
 Width 11160.7 Hz
 2D Width 11160.7 Hz
 2 repetitions
 128 increments
 OBSERVE H1, 699.7567660 MHz
 DATA PROCESSING
 Sq. sine bell 0.075 sec
 F1 DATA PROCESSING
 Sq. sine bell 0.011 sec
 FT size 4096 x 4096
 Total time 5 min 40 sec



8k




Sample Name:
 Data Collected on:
 Yb-vmars700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-120-NOESY-4tol
 Pulse Sequence: NOESY
 Solvent: cdcl3
 Data collected on: Dec 10 2012
 Operator: nbabij
 Relax. delay 1.000 sec
 Acq. time 0.150 sec
 Width 5868.5 Hz
 2D Width 5868.5 Hz
 4 repetitions
 2 x 128 increments
 OBSERVE H1, 699.7567660 MHz
 DATA PROCESSING
 Gauss apodization 0.069 sec
 F1 DATA PROCESSING
 Gauss apodization 0.020 sec
 FT size 2048 x 2048
 Total time 24 min



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\IRACEMIC-NRB-4-55-pCl-TOLYL-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-55-pCl-TOLYL-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-55-pCl-TOLYL-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 8/8/2012 2:44:19 PM
 Data Processed : 8/8/2012 3:10:15 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	16.956	44268953	1299090	50.371
2	18.366	43617224	974723	49.629
Total		87886176	2273813	100.000



==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABU\CHIRAL-NRB-4-92-2-pCl-4-TOLYL-100-NAOtBU-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-92-2-pCl-TOLYL-100-NAOtBU-SSIPHOSPE-5%IPA-0.75ml_m
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-92-2-pCl-4-TOLYL-100-NAOtBU-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 9/28/2012 4:49:24 PM
 Data Processed : 9/28/2012 5:13:26 PM


<Chromatogram>





1 PDA Multi 1/254nm 4nm

PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	17.335	16104566	506093	92.981
2	19.436	1215674	32944	7.019
Total		17320240	539037	100.000



Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-105-X-B-1H-4-OMe
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Oct 25 2012




Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: CARBON
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Oct 25 2012



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\IRACEMIC-NRB-4-86-pCl-OMe-100-PCY3-3%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-86-pCl-OMe-100-PCY3-3%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-86-pCl-OMe-100-PCY3-3%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 11/29/2012 6:05:51 PM
 Data Processed : 11/29/2012 7:24:45 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	48.326	123683130	1316190	50.164
2	52.485	122874255	830445	49.836
Total		246557385	2146635	100.000



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-116-pCl-4-OMe-21-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-116-pCl-4-OMe-21-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-116-pCl-4-OMe-21-100-NaOtBu-SSIPHOSPE-3%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 11/29/2012 4:44:16 PM
 Data Processed : 11/29/2012 6:04:21 PM

<Chromatogram>





PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	49.292	41066585	412959	92.385
2	55.654	3384865	26148	7.615
Total		44451450	439107	100.000




Sample Name:
Data Collected on:
Yb-vnms700
Archive directory:
Sample directory:
FidFile: NRB-4-105-E-X-1H-Ph
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Oct 25 2012



Sample Name:
Data Collected on:
Yb-vnms700
Archive directory:
Sample directory:
FidFile: NRB-4-105-E-X-13C-Ph
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Oct 25 2012


Agilent Technologies



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-96-pCl-PHENYL-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-96-pCl-PHENYL-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-96-pCl-PHENYL-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/10/2012 2:52:59 PM
 Data Processed : 10/10/2012 3:24:59 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	21.348	6370242	157244	50.083
2	24.417	6349172	118480	49.917
Total		12719414	275724	100.000



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-96-pCl-PHENYL-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-96-pCl-PHENYL-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_mi
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-96-pCl-PHENYL-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/10/2012 3:37:24 PM
 Data Processed : 10/10/2012 4:11:56 PM

<Chromatogram>





PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	21.087	32587442	843023	90.230
2	24.216	3528682	67790	9.770
Total		36116124	910813	100.000




8m

Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-136-X-1H-CF3
Pulse Sequence: PROTON (s2pu1)
Solvent: cdcl3
Data collected on: Dec 21 2012



Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-107-C-X-13C
Pulse Sequence: CARBON (s2pu1)
Solvent: cdcl3
Data collected on: Nov 1 2012


Agilent Technologies



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-58-pCl-CF3-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-58-pCl-CF3-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-58-pCl-CF3-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 8/10/2012 1:42:35 PM
 Data Processed : 8/10/2012 2:12:09 PM

<Chromatogram>



PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	19.836	31756926	766828	49.635
2	26.478	32223518	510700	50.365
Total		63980444	1277528	100.000



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-107-pCl-4-CF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-107-pCl-4-CF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_m
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-107-pCl-4-CF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 11/1/2012 1:56:29 PM
 Data Processed : 11/1/2012 2:29:27 PM

<Chromatogram>



PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	19.852	55981453	1343838	84.851
2	27.472	9994947	167907	15.149
Total		65976400	1511745	100.000




8n (with NaOtBu)

==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-83-pCl-CF3-95-NAOME-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-83-pCl-CF3-95-NAOME-SSIPHOSPE-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-83-pCl-CF3-95-NAOME-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 9/13/2012 7:30:51 PM
 Data Processed : 9/13/2012 8:02:40 PM

<Chromatogram>





PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	19.403	71981301	1731362	90.036
2	26.668	7966346	131922	9.964
Total		79947647	1863284	100.000




8n (with NaOMe)

Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-105-X-C-1H-OCF3
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Oct 25 2012



Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-105-X-C-13C-OCF3
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Oct 25 2012


Agilent Technologies




==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABU\RACEMIC-NRB-4-58-pCl-OCF3-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-58-pCl-OCF3-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-58-pCl-OCF3-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 8/10/2012 2:14:53 PM
 Data Processed : 8/10/2012 2:40:44 PM

<Chromatogram>




PeakTable				
Peak#	Ret. Time	Area	Height	Area %
1	16.766	13936711	401672	50.472
2	19.105	13675829	298353	49.528
Total		27612540	700025	100.000



==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-94-pCl-4-OCF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-94-pCl-4-OCF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_mi
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-94-pCl-4-OCF3-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/4/2012 10:46:14 AM
 Data Processed : 10/4/2012 11:09:47 AM


<Chromatogram>



PeakTable

PDA Ch1 245nm 4nm

Peak#	Ret. Time	Area	Height	Area %
1	17.124	74360169	1711279	87.935
2	19.768	10202360	209358	12.065
Total		84562529	1920637	100.000




8o (with NaOtBu)

==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABIJ\CHIRAL-NRB-4-137-II-pCl-OCF3-100-NaOMe-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-137-I-pCl-OCF3-100-NaOMe-SSIPHOSPE-5%IPA-0.75ml_mi
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-137-II-pCl-OCF3-100-NaOMe-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 12/23/2012 5:45:35 PM
 Data Processed : 12/23/2012 6:13:19 PM

<Chromatogram>





PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	16.764	31880825	954387	92.755
2	19.756	2490104	57122	7.245
Total		34370929	1011509	100.000




8o (with NaOMe)

Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-121-X-3OMe
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Dec 6 2012



Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-105-D-X-13C-3OMe
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Oct 25 2012


Agilent Technologies




==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-90-pCl-3-OMe-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-90-pCl-3-OMe-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-90-pCl-3-OMe-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 9/25/2012 7:29:03 PM
 Data Processed : 9/25/2012 8:05:08 PM

<Chromatogram>



PeakTable				
Peak#	Ret. Time	Area	Height	Area %
1	27.381	48187230	552654	49.026
2	30.736	50102213	843446	50.974
Total		98289443	1396100	100.000




8p

==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-94-pCl-3-OMe-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-94-pCl-3-OMe-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-94-pCl-3-OMe-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/4/2012 3:33:10 PM
 Data Processed : 10/4/2012 4:08:43 PM

<Chromatogram>





PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	27.173	5497076	67634	12.683
2	30.594	37845830	483921	87.317
Total		43342907	551556	100.000



Sample Name:
 Data Collected on:
 YB-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-117-X-1H-2naphthyl
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Dec 1 2012




Sample Name:
 Data Collected on:
 YB-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-107-B-X-13C
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Nov 1 2012



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-90-pCl-2-naphthyl-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-90-pCl-2-naphthyl-100-PCY3-5%IPA-0.75ml_min.lcd
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-90-pCl-2-naphthyl-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 9/26/2012 1:51:54 PM
 Data Processed : 9/26/2012 2:25:26 PM

<Chromatogram>



PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	24.856	45755831	941390	49.764
2	28.662	46190576	639545	50.236
Total		91946407	1580935	100.000




==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-107-2-pCl-2-naphyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-107-2-pCl-2-naph-100-SSIPHOSPE-5%IPA-0.75ml_
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-107-2-pCl-2-naphyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/31/2012 5:21:45 PM
 Data Processed : 10/31/2012 6:05:47 PM


<Chromatogram>

C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-107-2-pCl-2-naphyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 mAU





PeakTable


Peak#	Ret. Time	Area	Height	Area %
1	24.372	129657052	2544179	87.682
2	28.231	18215094	271035	12.318
Total		147872146	2815214	100.000



Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-116-K-1H-2tol
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Nov 30 2012




Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-107-X-A-13C
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Nov 1 2012



==== Shimadzu LCsolution Analysis Report ====


C:\LabSolutions\Data\BABI\RACEMIC-NRB-4-90-pCl-2-tolyl-100-PCY3-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : RACEMIC-NRB-4-90-pCl-2-tolyl-100-PCY3-5%IPA-0.75ml_min
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : RACEMIC-NRB-4-90-pCl-2-tolyl-100-PCY3-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 9/26/2012 11:30:07 AM
 Data Processed : 9/26/2012 12:10:21 PM

<Chromatogram>



PeakTable

Peak#	Ret. Time	Area	Height	Area %
1	19.869	39671328	972024	49.912
2	23.795	39810829	618614	50.088
Total		79482157	1590638	100.000




8r

==== Shimadzu LCsolution Analysis Report ====

C:\LabSolutions\Data\BABI\CHIRAL-NRB-4-107-pCl-2-tolyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Acquired by : Admin
 Sample Name : CHIRAL-NRB-4-107-pCl-2-tolyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_
 Sample ID : <SAMPLE>
 Tray# : 1
 Vial # : 1
 Injection Volume : 1 uL
 Data File Name : CHIRAL-NRB-4-107-pCl-2-tolyl-100-NaOtBu-SSIPHOSPE-5%IPA-0.75ml_min.lcd
 Method File Name : Cyclic Urea Method.lcm
 Batch File Name :
 Report File Name : Default.lcr
 Data Acquired : 10/31/2012 3:36:37 PM
 Data Processed : 10/31/2012 4:33:50 PM


<Chromatogram>




1 PDA Multi 1/215nm 4nm

PeakTable


PDA Ch1 215nm 4nm				
Peak#	Ret. Time	Area	Height	Area %
1	20.144	12340532	334865	70.853
2	24.282	5076517	94929	29.147
Total		17417049	429794	100.000



Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-110-1R
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Nov 13 2012




Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-118-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Dec 1 2012




Sample Name:
Data Collected on:
Sn.Chem.LSA.UMich.edu-inova500
Archive directory:
Sample directory:
FidFile: NRB-4-122-1H
Pulse Sequence: PROTON (s2pu1)
Solvent: cdcl3
Data collected on: Dec 13 2012

Agilent Technologies




9



Sample Name:
Data Collected on:
Yb-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-4-126-X-13C
Pulse Sequence: CARBON (s2pu1)
Solvent: cdcl3
Data collected on: Dec 18 2012

Agilent Technologies



STANDARD 1H OBSERVE - profile

Sample Name:

Data Collected on:

Yb-vnmrs700

Archive directory:

Sample directory:


FidFile: NRB-4-100-1H-guanidine

Pulse Sequence: PROTON (s2pul)


Solvent: cdcl3

Data collected on: Feb 4 2013

Agilent Technologies



10



Sample Name:

Data Collected on:

Yb-vnmrs700

Archive directory:

Sample directory:


FidFile: NRB-4-100-13C

Pulse Sequence: CARBON (s2pul)

Solvent: cdcl3

Data collected on: Oct 23 2012


Agilent Technologies




STANDARD PROTON PARAMETERS

Sample Name:
 Data Collected on:
 Te-vnmrs500
 Archive directory:
 Sample directory:
 FidFile: NRB-4-158-A-1H
 Pulse Sequence: PROTON (s2pul)
 Solvent: cdcl3
 Data collected on: Feb 19 2013

Agilent Technologies




12



Sample Name:
 Data Collected on:
 Yb-vnmrs700
 Archive directory:
 Sample directory:
 FidFile: NRB-4-158-13C
 Pulse Sequence: CARBON (s2pul)
 Solvent: cdcl3
 Data collected on: Feb 19 2013

Agilent Technologies



STANDARD 1H OBSERVE - profile

Agilent Technologies

Sample Name:

Data Collected on:
Yb-vmars700

Archive directory:

Sample directory:

FidFile: NRB-4-158-cosy

Pulse Sequence: gCOSY
Solvent: cdcl3
Data collected on: Feb 19 2013

Operator: nbabij

Relax. delay 1.000 sec
Acq. time 0.150 sec
Width 6983.2 Hz
2D Width 6983.2 Hz
2 repetitions
128 increments

OBSERVE H1, 699.7567665 MHz

DATA PROCESSING


Sq. sine bell 0.075 sec

F1 DATA PROCESSING


Sq. sine bell 0.018 sec

FT size 4096 x 4096

Total time 5 min 41 sec



12



STANDARD 1H OBSERVE - profile

Agilent Technologies

Sample Name:

Data Collected on:
Yb-vmars700

Archive directory:

Sample directory:

FidFile: NRB-4-158-NOESY

Pulse Sequence: NOESY
Solvent: cdcl3
Data collected on: Feb 20 2013

Operator: nbabij

Relax. delay 1.000 sec
Acq. time 0.150 sec
Width 6983.2 Hz
2D Width 6983.2 Hz
4 repetitions
2 x 200 increments

OBSERVE H1, 699.7567665 MHz

DATA PROCESSING


Gauss apodization 0.069 sec

F1 DATA PROCESSING

Gauss apodization 0.026 sec

FT size 4096 x 4096

Total time 37 min



Automated Probe tuning parameter

Sample Name:

Data Collected on:
yb.chem.lsa.umich.edu-vmrs700


Archive directory:

Sample directory:

FidFile: NRB-5-010-1H

Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: May 26 2013

Agilent Technologies



Sample Name:

Data Collected on:
yb.chem.lsa.umich.edu-vmrs700


Archive directory:

Sample directory:

FidFile: CARBON

Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: May 26 2013

Agilent Technologies



Automated Probe tuning parameter

Sample Name:


Data Collected on:
yb.chem.lsa.umich.edu-vnmrs700
Archive directory:

Sample directory:


FidFile: NRB-5-012-1H

Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: May 27 2013

Agilent Technologies



14



Automated Probe tuning parameter

Sample Name:


Data Collected on:
yb.chem.lsa.umich.edu-vnmrs700
Archive directory:

Sample directory:

FidFile: NRB-5-012-13C

Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: May 27 2013


Agilent Technologies




Automated Probe tuning parameter

Agilent Technologies

Sample Name:
Data Collected on:
yb.chem.lsa.umich.edu-vmrs700
Archive directory:
Sample directory:
FidFile: NRB-5-017-1H
Pulse Sequence: PROTON (s2pul)
Solvent: cdcl3
Data collected on: Jun 10 2013




9-*epi*-Batzelladine K (16)
CDCl₃



Automated Probe tuning parameter

Agilent Technologies

Sample Name:
Data Collected on:
yb.chem.lsa.umich.edu-vmrs700
Archive directory:
Sample directory:
FidFile: NRB-5-017-13C
Pulse Sequence: CARBON (s2pul)
Solvent: cdcl3
Data collected on: Jun 10 2013




Automated Probe tuning parameter

Sample Name:
Data Collected on:
yb.chem.lsa.umich.edu-vnmrs700
Archive directory:


Sample directory:
FidFile: NRB-5-017-1H-CD3OD

Pulse Sequence: PROTON (s2pul)
Solvent: cd3od
Data collected on: Jun 10 2013



Agilent Technologies

9-*epi*-Batzelladine K (16)
CD₃OD




Automated Probe tuning parameter

Sample Name:
Data Collected on:
yb.chem.lsa.umich.edu-vnmrs700
Archive directory:

Sample directory:
FidFile: NRB-5-017-13C-CD3OD

Pulse Sequence: CARBON (s2pul)
Solvent: cd3od
Data collected on: Jun 10 2013

Agilent Technologies




Automated Probe tuning parameter

Sample Name:
Data Collected on:
yb.chem.lsa.umich.edu-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-5-017-cosy


Pulse Sequence: gCOSY
Solvent: cd3od
Data collected on: Jun 10 2013

Temp. 25.0 C / 298.1 K
Operator: nbabij

Relax. delay 1.000 sec
Acq. time 0.150 sec
Width 3491.6 Hz
2D Width 3491.6 Hz
2 repetitions
128 increments
OBSERVE H1, 699.7595207 MHz
DATA PROCESSING
Sq. sine bell 0.075 sec
F1 DATA PROCESSING
Sq. sine bell 0.037 sec
FT size 2048 x 2048
Total time 5 min 44 sec



9-*epi*-Batzelladine K (16)
CD₃OD




Proton Spectrum

Sample Name:
Data Collected on:
yb.chem.lsa.umich.edu-vnmrs700
Archive directory:
Sample directory:
FidFile: NRB-5-017-noesy

Pulse Sequence: NOESY
Solvent: cd3od
Data collected on: Jun 10 2013

Temp. 25.0 C / 298.1 K
Operator: nbabij

Relax. delay 1.000 sec
Acq. time 0.150 sec
Width 11160.7 Hz
2D Width 11160.7 Hz
4 repetitions
2 x 200 increments
OBSERVE H1, 699.7595207 MHz
DATA PROCESSING
Gauss apodization 0.069 sec
F1 DATA PROCESSING
Gauss apodization 0.017 sec
FT size 4096 x 4096
Total time 37 min



9-*epi*-Batzelladine K (16)
CD₃OD